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Abstract

Background: Patients with cardiovascular disease (CVD) have a two-fold increased risk
of depression as compared to patients without CVD. According to the American Heart
Association (AHA, 2016), there is no gold-standard procedure for screening for
depression in cardiovascular patients. Screening for depression varies greatly across
specialties and practices, often leaving a gap for detection and treatment of depression in
cardiac patients. There are many depression screening tools available; however, the AHA
recommends use of the patient health questionnaire (PHQ) screening tool. The PHQ-2
and PHQ-9 questionnaires are the most brief, sensitive, and specific depression screening
tool for patients with cardiovascular disease.
Method: A quality improvement study was designed and implemented to determine the
usability of the PHQ screening tool in primary care and to compare the results of the
screening tools between practices. A descriptive pre-test and post-test survey design was
conducted to compare findings from two primary care settings, which utilized the PHQ
depression screening tool to screen for depression in cardiovascular patients. A total of 60
charts were audited, 30 charts from each practice. A retrospective chart review was
conducted at completion of the study in order to compare the results of depression
screenings and implemented treatments between the two practices.
Results: Of the 60 audited charts, 51 patients were screened for depression by their
primary care provider. After frequency distributions were calculated, it was noted that
v

29% of the sample population had depressive symptoms. This data is consistent with the
evidence-based literature that demonstrates that patients with cardiovascular disease are
at high risk for depression and should be routinely screened for depression in their
primary care homes as recommended by the American Heart Association (2016). Each of
these patients (n=15) who screened positive for depression was started on treatment for
depression at the time of the initial depression screening visit.
Implications: Findings from the quality improvement project underscored the need for
primary care providers to utilize the PHQ screening tool as the standard for screening in
patients with CVD due to the incidence of depression in cardiovascular patients and the
tool’s efficacy and ease of use. Depression screening in primary care should be included
in continuing medical education requirements for providers working in the primary care
setting. It is important to support all levels of government to adopt mental health policies
and to integrate mental health policy into public health policy and general social policy.
Additional research is needed to properly characterize evidence-based care of patients
with comorbid depression and cardiovascular disease.
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Chapter 1 Introduction
1.1 Description of the Clinical Problem
In patients with cardiovascular disease (CVD) seen in primary care, data suggests
a high prevalence rate for depression with several studies indicating that approximately
15-20% of patients who have had a myocardial infarction (MI) meet criteria for major
depressive disorder (Lichtman, Bigger, Blumenthal, and Frasure-Smith, 2008). An even
higher percentage of patients with CVD display an elevated level of depressive symptoms
that would meet criteria for other depressive disorders (Lichtman, et al., 2008).
According to Lichtman, et al., (2008), depression is frequently found in patients with
coronary heart disease (CHD) and is also independently associated with an increase in
cardiovascular morbidity and mortality (p. 1768). Among these patients, however,
depression is often underdiagnosed or misdiagnosed due to the patients’ other
comorbidities and the lack of standardized depression screening tools (McGuire, Ahearn,
and Doering, 2015).
Numerous studies have identified a significant correlation between depression,
increased risk of cardiovascular disease, and poor quality of life (Peters, Pinto, Beckett,
Swift, Potter, McCormack,…& Bulpitt, 2010; McGuire, et al., 2015; Mavrides &
Nemeroff, 2013). As Lichtman et al., (2008) discusses, “depression reduces the chances
of successful modifications of other cardiac risk factors and participation in cardiac
rehabilitation and is associated with higher healthcare utilization and costs and, not
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surprisingly, greatly reduced quality of life” (p. 1769). Depression is also
associated with a poorer prognosis for patients with cardiovascular disease (Peters, et al.,
2010).
McGuire, et al., (2015) suggests that there is a need for more research in
depression and cardiac patients due to costs, co-morbidities, and outcomes. Recently, the
American Heart Association assembled recommendations for primary care providers to
screen CVD patients for depression (Mavrides & Nemeroff, 2013). The purpose of this
study is to determine the best screening depression tool and implement the tool for early
detection of depression in primary care settings for patients with cardiovascular disease
1.2 Scope of the Clinical Problem
Patients with cardiovascular disease have a two-fold increased risk of depression
as compared to patients without heart disease (Kronish, Krupka, & Davidson, 2012, p.
126). Similarly, Lichtman et al., (2008) also discusses that depression is approximately
three times more common in patients after they have had an acute myocardial infarction
(AMI) as compared to the general population (p. 1768).
In terms of cost, it is estimated that the economic impact of depression in the
United States ranges from a devastating $20 billion to $45 billion annually, rivaling the
costs of chronic diseases such as hypertension (Rutledge, Vaccarino, Johnson, Bittner,
Olson, Linke,…Shaw, 2009). Even minor depression has been shown to increase
economic burden (Rutledge et al., 2009). According to Rutledge, et al., (2009),
depression is associated with a 15% to 53% increase in 5-year cardiovascular costs.
These costs have been described as direct and indirect. Direct costs include
hospitalizations, office visits, procedures, and medications; whereas, indirect costs
2

include out-of-pocket expenses, lost productivity and wages, and travel (Rutledge, et al.,
2009, p. 176).
In terms of health comorbidities, CVD and Depression are both highly prevalent,
coexisting diseases (Paz-Filho, Licinio, & Wong, 2010). They share common
pathophysiological etiologies or co-morbidities, such as cardiac rhythm disturbances
alterations in the hypothalamic-pituitary axis, and hemorheologic, inflammatory and
serotoninergic changes (Paz-Filho, 2010). There is compelling evidence that depression is
an independent risk factor for both the development of CVD and for worsening prognosis
once CVD is established (Paz-Filho, 2010). Evidence has also shown that patients with
CVD may become depressed as a response to the burden of a co-morbid condition (PazFilho, 2010).
In addition to the co-morbidity correlation between CVD and Depression, there is
strong evidence to suggest that depression is associated with an increased risk of
cardiovascular disease and cardiac death (Glassman, 2007). Patients with depression and
comorbid CVD have a higher mortality rate than the general population (Hare, Toukhsati,
Johansson, & Jaarsma, 2014). Evidence has shown a severity relationship between
depression and CVD: the more severe the depression, the higher the subsequent risk of
mortality and other cardiovascular events (Hare et al., 2014). Furthermore, short-term
prognosis is found between these co-morbidities (Jiang, Alexander, Christopher,
Kuchibhatla, Gaulden, Cuffe,…O’Connor, 2001).
For psychosocial effects of CVD and depression, evidence suggests that
dysfunctional personal relationships or family responsibilities are correlated for elevated
CVD risk (Low, Thurston, & Matthews, 2010). Supportive social relationships and
3

positive psychological factors are associated with reduced risk of depression in patients
with CVD, as well as reduced risk of morbidity and mortality associated with CVD (Low,
et al., 2010). Consideration of psychosocial factors may improve the identification of
patients at elevated risk for CVD and depression, and may also lead to the development
of effective psychological interventions for patients with or at risk for CVD (Low, et al.,
2010). Moreover, evidence suggests that social and family support play important roles
in CVD and mental health (Healthy People 2020). In other words, stress related to
interpersonal relationships and family responsibilities has been shown to be an important
risk factor in the development of CVD (Low, et al., 2010).
Decreased sexual activity and sexual dysfunction are common in patients with
CVD and can increase depression (Armstrong, 2012). Changes in sexual activity after a
cardiac event may impair a patient’s quality of life and may negatively affect
psychological health (Armstrong, 2012). The resulting anxiety and depression may be an
important contributing cause of sexual dysfunction, including decreased libido, difficulty
with arousal and orgasm, and dyspareunia (Armstrong, 2012).
Finally, hospital readmission rates and depression are common. Data show that
patients with major depression and cardiovascular disease have increased readmissions
and lengthier hospital stays (Jiang, et al., 2001). In one study, patients with CHF who had
major depression were more than twice as likely as non-depressed patients to die or be
readmitted within 3 months to 1 year after hospitalization (Jiang, et al., 2001).

4

1.3 Analysis of Current Practice
According to McGuire et al., (2015), there continues to be a significant practice
gap in relation to screening, referral, and treatment of depression in CVD patients (p.
427). Although the American Heart Association recommends routine screening for
depression in patients with cardiovascular disease, there are conflicting opinions among
healthcare providers with regard to timing of screening and location of screening,
especially in cardiology and primary care settings (Kronish, et al., 2012). Much of the
research on depression in patients with CVD disease has occurred in the acute care
setting (Lichtman, et al., 2008). With the emphasis in primary care management,
improving outcomes, and decreasing hospital readmissions, primary care screening for
depression in patients with CVD is essential and the ideal opportunity for long-term
management (Kronish, et al., 2012).
Currently, there is no standardized depression screening template for patients with
cardiovascular disease in the primary care setting (Kronish, et al., 2012). There are many
depression screening tools available for the primary care setting; however, the American
Heart Association recommends the use of tools such as the Patient Health Questionnaire
2-item screening tool (PHQ-2) and/or Patient Health Questionnaire nine-item screening
tool (PHQ-9) due to the ease of use, reliability, and validity of the PHQ questionnaires
(McGuire, et al., 2015, p. 429). The PHQ has also been easily implemented into
electronic medical record (EMR) systems for general use. Ideally, implementation of
these screening tools into the EMR would routinely alert the provider to perform the
screening.
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The PHQ-2 comprises the first two questions in the PHQ-9 questionnaire. As
McGuire, et al., (2015) discusses, the PHQ-2 screening scale is the best brief screening
instrument for use during a routine visit intake or annual physical examination survey.
According to the American Psychological Association (2016), the PHQ-2 inquires about
the degree to which an individual has experienced a depressed mood and anhedonia over
the past two weeks. Its purpose is not to establish a final diagnosis or to monitor
depression severity, but rather to screen for depression (APA, 2016). Patients who screen
positive should be further evaluated with the PHQ-9 to determine whether they meet
criteria for a depressive disorder (APA, 2016). If the PHQ-2 is negative, the provider may
continue with the remainder of the assessment and does not need to complete the PHQ-9
unless desired (McGuire, et al., 2015).
The PHQ-9 is a nine-item self-report measure developed to diagnose the presence
and severity of depression in primary care (Stafford, Hons, Berk, & Jackson, 2007). It is
based directly on DSM-IV diagnostic criteria for major depression (Stafford, et al., 2007).
It has the potential of being a dual-purpose instrument that, with the same nine items, can
establish depressive disorder diagnoses using a categorical algorithm and grade the
depressive symptom severity (Stafford, et al., 2007). As a severity measure, the score on
the PHQ-9 can range from 0 to 27. Scores of 5, 10, 15 and 20 represent thresholds
demarcating the lower limits of mild, moderate, moderately severe and severe depression,
respectively (Stafford, et al., 2007). In multiple studies, PHQ-9 scores > 10 have been
found to have a sensitivity of 88% and a specificity of 88% for Major Depressive
Disorder (APA, 2016).
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The PHQ questionnaires have been shown to be valid and reliable and have been widely
utilized in studies with cardiac patients (Stafford, et al., 2007). The opportunity to screen
for depression in cardiac patients should not be missed, as effective treatment of
depression in these patients will lead to improved health outcomes (McGuire et al.,
2015).
1.4 Discussion of Practice Innovation/Best Practices to Address Problem
Early detection of depression in patients with cardiovascular disease has been
shown to improve outcomes in these patients (Lichtman, et al., 2008). During primary
care visits, the provider should administer the simple and quick PHQ-2 question survey in
order to screen for depression, thereby, following AHA guidelines and recommendations.
Studies have shown that these patients are not routinely screened for depression in other
settings (Kronish, et al., 2012).
1.5 Statement of the Purpose/Problem
The purpose of this evidence-based project is to implement a standardized
approach for depression screening for cardiovascular patients in the primary care setting
in order to more accurately and efficiently assess the severity of depression in these
patients and treat them in a timelier manner. Currently, there is not a routine screening
process for depression in the primary care setting for cardiovascular patients.
1.6 Project Questions
What is the best depression screening tool for implementing into a primary care
setting for screening among patients with CVD for early detection? What evidence
identifies timely and efficient screening of depression in patients with cardiovascular
7

disease? What research is available on the importance of detection of depression in
cardiac patients? What research is available on depression screening in the primary care
setting?
1.7 PICOT Question and Definitions
For providers in primary care settings who manage CVD patients, is the use of
PHQ questionnaires utilized as a depression screening tool more efficient and effective as
compared to no routine screening and sporadic screening with multiple tools? The
population (P) in this study is providers in primary care who manage primary care
patients with cardiovascular disease, and the intervention (I) is providers utilizing the best
screening tool for depression in patients with CVD. The following will be measures to
assess the intervention: screening for depression, medication therapy, and referral for
counseling. The comparison (C) for this study is the current practice of providers’
utilization of multiple tools for screening for depression in CVD patients; however, there
is no routine, standardized process in place in primary care settings. The outcome (O)
will be to identify and implement the best screening tool for depression in patients with
CVD.
1.8 Definitions
1. Depression. The Diagnostic and Statistical Manual of Mental Disorders, 4th edition
(DSM-IV, 2000) describes depression as a depressed mood and/or loss of interest or
pleasure in life activities for a duration of at least two weeks and at least five of the
following symptoms that cause clinically significant impairment in social, work, or other
important areas of daily functioning
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Table 1.1 PICOT Definitions
Population

Current

Intervention

Outcome

Time

Practice
60 patients

Currently,

Providers use

Identify and

6-month review

age 18 years

providers use

the best

Implement the

of

and older with

multiple tools

Screening Tool

best screening

implementation

documented

for Screening

for Depression

tool for

of depression

cardiovascular for Depression in Patients with

depression in

screening for 30

disease (chart

in Primary

Primary Care

patients at

audits).

Care patients

patients with

routine Primary

Providers in

with CV

CVD as

Care visits

Primary Care

disease, but no

measured by:

who manage

standardized

50% provider

Primary Care

screening

documentation

patients with

process

of using the

CV disease.

CV disease

screening tool
and
subsequent
management
(counseling,
medication)
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Depressed mood most of the day, diminished interest or pleasure in all or most
activities; significant unintentional fluctuations in weight; insomnia or
hypersomnia; agitation or psychomotor dysfunction; fatigue or loss of energy,
feelings of worthlessness or guilt; diminished ability to think or concentrate;
and suicidality (USDHHS, 2008).
1. Cardiovascular Disease. The American Heart Association (2016) describes
cardiovascular disease as a multitude of individual diseases of the heart and
vasculature, including structural heart disorders and blood clots.
2. Screening Tools. A screening tool is a simple test which is performed on a
large number of people to identify those who have or are likely to develop a
specific disease. Often these screening tests have a high sensitivity and
moderate specificity (Medical Dictionary, 2016).
3. Primary Care. Primary care is the level of a health system that provides entry
into the system for all new needs and problems, and it provides a home for
patients to manage new problems as well as chronic conditions.
4. Health Care Provider. A health care provider is defined as one who renders
medical care or health services to patients, including physicians, nurse
practitioners, physician assistants, and others (Medical Dictionary, 2016).
5. Adult Patients. An adult patient will be defined as a patient who is 18 years
of age or older with cardiovascular disease.
1.9 Assumptions
Patients diagnosed with cardiovascular disease deserve routine, standardized
screening of depression in primary care settings since depression may severely affect
10

morbidity and mortality. Evaluation of evidenced-based practice can identify best
practice measures to identify and treat depression in this population. Implementation of
depression screening tools can reduce suffering of patients and yield better outcomes for
their overall health status. PHQ-2 and PHQ-9 questionnaires are effective and efficient
screening tools for depression, and the American Heart Association has strongly
recommended these tools as the gold standard for cardiovascular patients. Provider
education is imperative to understanding the importance of detection and treatment of
depression in these patients. Identifying and appraising quality evidence from current
research is important to change current clinical practice guidelines that lead to improved
patient outcomes.
1.10 Chapter Summary
Depression and CVD are highly prevalent in the United States. Persons with CVD
have more depression than the general population. Persons with depression are more
likely to eventually develop CVD and also have a higher mortality rate than the general
population. In order to minimize morbidity and mortality, it is crucial to understand that
depression and CVD are frequently co-morbid and that both conditions should be treated
concomitantly. To screen for depression in these patients, an appropriate, standardized
screening approach should be utilized by providers and staff. The PHQ screening tools
are a cost-effective, reliable, valid, and time-efficient approach to improving patients’
quality of life.
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Chapter 2 Literature Review
Evidence-based research has been utilized to facilitate process improvement in
our continuously evolving healthcare system. It has been essential for healthcare
clinicians to possess the skills of critically appraising evidence and distinguish best
evidence from unreliable evidence (Melnyk & Fineout-Overholt, 2015). A systematic
literature review was performed with the purpose of identifying evidence that supports
screening for depression in primary care patients with cardiovascular disease. The
purpose of this study is to determine the best screening depression tool and implement the
tool for early detection of depression in primary care settings for patients with
cardiovascular disease.
2.1 Search Methodology
The identification of depression screening tools utilized in cardiac patients was
generated based on a comprehensive search of databases accessed through the University
of South Carolina’s online library. The literature has been extensively reviewed through
use of CINAHL Complete and Cochrane Library electronic databases. The most frequent
key words and phrases that were used in the searches included “depression,”
“cardiovascular,” and “screening.” These specific search terms focus on the PICOT
question and definitions. For the majority of the search iterations, the search terms
“depression” and “cardiovascular” were used together or with an additional modifier.
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The initial search was undertaken in CINAHL Complete (2006-2016) through the
Thomas Cooper Library. The limiters “Full Text” and “English” were utilized for all
searches within this database. For the initial search, the terms “depression” and
“cardiovascular” were used, and this search returned 1,004 results, which was further
narrowed by the third search term “screening.” This search yielded a total of 53 results of
which four articles were chosen due to relevance to PICOT question and due to the high
quality of evidence. Another similar search in CINAHL included the search terms
“depression,” “cardiovascular,” and the additional modifier “randomized trial.” This
search resulted in 48 articles, and four of these articles were found to be applicable to the
PICOT question.
The next search was conducted in Cochrane Library with limiters of “Trials” and
“2006-2016.” The search terms utilized for this search were “depression, coronary heart
disease, and randomized.” This search yielded 51 results of which four articles were
chosen for relevance to the PICOT question. Another search was undertaken in CINAHL
Complete with the keywords “depression” and “coronary heart disease,” and this search
returned 19 results of which three were found to be applicable to the PICOT question.
Inclusion and exclusion criteria were established for the purpose of selecting
appropriate studies to address the PICOT question. For inclusion criteria, the searches
were limited to English language articles only. Also, higher levels of evidence were the
only types of articles included in the selection process, specifically Levels I-IV (Melnyk
& Fineout-Overholt, 2015). Evidence ratings (Level I-IV) and quality ratings for the
literature are based on Dearholt & Dang’s (2012) book John Hopkins Nursing EvidenceBased Practice: Model and Guidelines.
13

Exclusion criteria included non-English language studies, as well as studies published
before 2006. There were many descriptive and qualitative studies in several of the
searches, but these were excluded from the evidence table at this time due to evidence
ratings. However, several of the descriptive and qualitative studies were set aside due to
quality ratings.
After evaluation of the articles using inclusion and exclusion criteria, the choices
were narrowed to fifteen articles which were most appropriate for the topic and were
good to high quality evidence. In the evidence table (see Appendix A), there are fifteen
articles, which are Level I through Level IV evidence according to John Hopkins’ model
(Dearholt & Dang, 2012). There are a variety of types of studies contained within the
table, including systematic reviews, meta-analyses, randomized controlled trials, a quasiexperimental study, cohort studies, and clinical practice guidelines from the American
Heart Association. Of the fifteen included articles, there are 5 randomized controlled
trials, and several of these are double-blind studies. According to Melnyk and FineoutOverholt (2015), “randomized control trials are the most appropriate research design to
answer questions of efficacy and effectiveness of interventions because their
methodology provides confidence in establishing cause and effect” (p. 116).
According to Melnyk and Fineout-Overholt (2015), critical appraisal hinges on
validity, reliability, and applicability (p.87). The database search generated the fifteen
selected articles that were placed in a literature review table (see Appendix A) then
utilized for their analysis and synthesis. In this table, there is discussion of the limitations
of each study, including threats to internal validity, external validity, and reliability.
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2.2 Analysis of Evidence
Current research has been analyzed to identify common symptoms,
pathophysiology, treatment, and implementation of screening tools for depression in
patients with cardiovascular disease. Analysis of literature has been a significant process
utilized to support changes in current practice, policies, and guidelines.
Depression Symptoms and Comorbidities. Dysphoria, insomnia or
hypersomnia, anhedonia, fatigue or loss of energy, increased guilt or worthlessness,
decreased concentration, appetite changes, psychomotor dysfunction, and suicidal
ideation are the symptoms of depression and exist on a vast continuum of severity and
complexity (McGuire et al., 2015, pp. 422-423). In one double-blind randomized control
trial, higher depression scores were associated with an increased risk of a subsequent
cardiovascular event, mortality, and possibly dementia (Peters, Pinto, Beckett, Swift,
Potter, McCormack,… Bulpitt, 2010). This was a double-blind RCT of 2,656
participants. The HYVET was a randomized double-blind, placebo-controlled trial and
employed an antihypertensive treatment regimen of indapamide sustained release 1.5 mg
with the optional addition of perindopril 2–4 mg. Ethical and regulatory approvals were
obtained prior to data collection. Depression scores were collected using the 15-item
GDS (geriatric depression scale) administered as part of a Quality of Life (QoL)
questionnaire at baseline and annually thereafter (Peters, et al., 2010). The researchers
found that a GDS score of ≥6 was associated with an increased risk of all-cause and
cardiovascular mortality and cardiovascular morbidity. Mood was found to be worse in
those who previously had a cardiac event. GDS score ≥6 was associated with increased
risks of all-cause (HR 1.8, 95% CI: 1.4–2.3; p <0.001) and cardiovascular mortality (HR
15

2.10, 95% CI: 1.5–3.0; p <0.001), all stroke (HR 1.8, 95% CI: 1.2–2.8; p 0.002) and all
cardiovascular events (HR 1.6, 95% CI: 1.2–2.1; p 0.001). Risk of incident dementia also
tended to be increased (HR 1.28, 95% CI: 0.95–1.73; p 0.110). This study also found that
there is an increased risk of all-cause and cardiovascular mortality and cardiovascular
morbidity in patients who suffer from the above listed depressive symptoms (Peters, et
al., 2010).
The study concluded that a depressed mood is common in older people with
hypertension (Peters, et al., 2010). Higher depression scores were associated with an
increased risk of a subsequent cardiovascular event, mortality and possibly dementia
(Peters, et al., 2010). The researchers suggest that further studies would require
replication and exclusion of some alternative possibilities before testing in an
intervention trial (Peters, et al., 2010).
This double-blind RCT helps to significantly minimize threats to internal validity
by reducing selection bias (Dearholt & Dang, 2012). The size of the study was large
which minimizes threats to validity. The subjects in each of the groups were similar with
regard to demographic and baseline clinical variables, which makes the results more
generalizable. Baseline demographics were clearly displayed in a table to complement the
discussion in the article. Although participants were unable to enter the study if they
required nursing care, the researchers did not collect rigorous information about activities
of daily living, disability levels or maintenance of social networks, socioeconomic status
or activity level. Therefore, there is the potential for uncontrolled confounding from
unmeasured factors. According to Dearholt and Dang (2012), the study is Level I
Evidence with a high quality rating (A).
16

Mavrides and Nemeroff (2013) found that the prevalence of major depressive
disorder (MDD) in patients with CAD, including stable and unstable angina or MI, is
estimated to be between 15 and 20%. They also found that another estimated 30–45%
have clinically significant depressive symptoms without meeting DSM-IV or DSM-V
(Diagnostic and Statistical Manual of Mental Disorders fourth and fifth editions) criteria
for MDD (Mavrides & Nemeroff, 2013, p. 329). This study was a systematic review of
61 randomized controlled clinical trials. PubMed and PsycINFO databases were searched
through July 2012. No trials were excluded, and the studies included were primarily from
North America and Europe. The search was completed with key words of
antidepressants, CVD, coronary artery syndrome, SSRIs, depression, treatment of
depression, post-MI, major depression, and cardiac disease (Mavrides & Nemeroff,
2013). These researchers found that depressive symptoms are especially prevalent in
patients recently hospitalized with acute cardiac events, with a depression prevalence rate
of 20-36% in patients recently hospitalized with congestive heart failure (Mavrides &
Nemeroff, 2013). In addition, depressive symptoms often persist indefinitely in patients
with CVD, partly due to under diagnosis and partly due to a lack of treatment or
inadequate treatment. In the progression of post-MI depression, symptoms generally
remain fairly consistent in terms of severity for up to 12 months (Mavrides & Nemeroff,
2013). Several mechanisms, behavioral and physiologic, have been implicated in the
connection between depression and cardiac disease, including alterations in platelet
function, inflammation, variability in heart rate, and adrenocortical hyperactivity
(Mavrides & Nemeroff, 2013, p. 330). The studies contained in this review are
randomized control clinical trials, and this helps to minimize threats to internal validity.
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The authors stated that they limited search results to the English language. By limiting to
English only, the researchers risk biasing the amount of research they may find with
regard to their research topic. The number of studies reviewed is 61, which helps to limit
threats to external validity. The results were consistent across all studies increasing the
generalizability of the results to the general population. The authors displayed their
results of all utilized clinical trials in an evidence table, and discussed odds ratios (OR),
effect sizes, and confidence intervals (CI) for the trials. The researchers compared the
results of each study, which limits threats to reliability in this review. Based on criteria by
Dearholt and Dang (2012), this study is Level I Evidence and has a high-quality rating
(A).
In one prospective cohort study with 960 participants, the researchers found that
higher baseline depressive symptoms over five years predicted greater risk of functional
decline in patients with CVD (Sin, Yaffe, & Whooley, 2014). Cardiovascular severity
assessments were obtained at baseline and again at 5 years. The severity of depressive
symptoms was assessed at baseline and at the 5-year follow-up using the 9-itme Patient
Health Questionnaire (PHQ). In models that tested each cardiovascular predictor
separately, baseline depressive symptoms and angina pectoris frequency were associated
with greater risk of functional decline during the 5-year period, whereas higher baseline
exercise capacity predicted lower risk of ADL and IADL decline (p < .001) (Sin, Yaffe,
& Whooley, 2014). These results suggest that efforts to treat and decrease depressive
symptoms may be as important as treating actual symptoms of cardiovascular disease to
enhance functional status (Sin, Yaffe, & Whooley, 2014). This study had a large sample
size, which strengthens the validity; however, the sample was largely male which limits
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the generalizability of the results (Sin et al., 2014). This study is Level III Evidence with
a quality rating of A (Dearholt & Dang, 2012).
In one systematic review, the literature revealed that CVD and Depression are
both highly prevalent diseases, which have been shown to frequently coexist (Paz-Filho,
Licinio, & Wong, 2010). This study is a literature review of a combination of RCTs,
quasi-experimental studies, and non-experimental studies in which the reviewers utilized
the PubMed database in order to describe the pathophysiological link between
cardiovascular disease and depression (Paz-Filho, 2010). In this study, researchers found
that depression and CVD share common pathophysiological etiologies or co-morbidities,
such as alterations in the hypothalamic-pituitary axis and serotoninergic changes (PazFilho, 2010). There is compelling evidence that depression is an independent risk factor
for both the development of CVD and for worsening prognosis (Paz-Filho, 2010).
Evidence has also shown that patients with CVD may become depressed as a
response to the burden of a co-morbid condition (Paz-Filho, 2010). Several nonexperimental studies were included in this review which increases the threat to internal
validity (Paz-Filho, 2010). The results were consistent across all studies increasing the
generalizability of the results to the general population (Paz-Filho, 2010). This study is
Level III Evidence with a good quality rating (B) (Dearholt & Dang, 2012).
In addition to the co-morbidity correlation between CVD and Depression, one
clinical review showed that there is strong evidence to suggest that depression is
associated with an increased risk of cardiovascular disease and cardiac death (Hare,
Toukhsati, Johansson, & Jaarsma, 2014). This is a clinical review of five major
randomized controlled trials with the purpose of evaluating the effects of anti-depressant
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pharmacotherapy on depression in cardiovascular disease settings (Hare, et al., 2014).
Researchers found that patients with depression and comorbid CVD have a higher
mortality rate than the general population (Hare, et al., 2014). Evidence has shown a
severity relationship between depression and CVD: the more severe the depression, the
higher the subsequent risk of mortality and other cardiovascular events (Hare, et al.,
2014). In this review, a total of five randomized control trials were reviewed, and the
researchers felt that these were all high quality evidence. The five trials included
significant numbers of patients ranging from 101 to 2,481 (Hare, et al., 2014). However,
the low number of studies included limits the validity of the review (Hare, et al., 2014).
This study is Level III Evidence with a good quality rating (B) (Dearholt & Dang, 2012).
Depression Screening. It is highly recommended to promptly assess depression
in patients with cardiovascular disease as it represents a crucial risk factor which may
result in worsening cardiac symptoms and premature death following cardiac events
(Mavrides & Nemeroff, 2013). Many screening tools are available for evaluation of
patients with depressive symptoms (Mavrides & Nemeroff, 2013).
The Hospital Anxiety and Depression Scale (HADS) is one of the simplest and
most widely utilized screening instruments for depression (Ceccarini, Manzoni, &
Castelnuovo, 2014). This screening tool utilizes a simple 14-item Likert-scale type of
scoring, and has been found to reliably detect depressive symptoms in post-MI patients in
the inpatient setting. The questionnaire was designed to provide a reliable tool within the
clinical practice and it is composed of 7 questions which identify the level of anxiety and
7 questions which relate to depression. The authors created this outcome measure
specifically to avoid excessive reliance on other aspects which are intertwined with
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anxiety and depression (Ceccarini, et al., 2014). Items of the Hospital Anxiety and
Depression Scale (HADS) are scored from 0 to 3 on a Likert scale with a final score
ranging from 0 to 21 for either anxiety or depression (Ceccarini, et al., 2014). The total
score is used as a measure of global mood disorder according to the classifications of
mild (8-10), moderate (11-15), and severe anxiety or depression (16-21). Zigmond and
Snaith (1983) performed the validation study for this screening tool. They found that
internal and test-retest reliabilities of both total and subscale scores were generally good
as the questionnaire allowed to determine subscale factors assessing dimensions of
anhedonia, anxiety, and psychomotor agitation (Ceccarini, et al., 2014). The Hospital
Anxiety and Depression Scale (HADS) is hence a reliable instrument useful to screen and
evaluate post-MI patients for symptoms of psychological distress. This tool has several
disadvantages or limitations, including its weakness in detecting actual severity of
depression (Ceccarini, et al., 2014).
Another tool, the Cognitive Behavioral Assessment Hospital Form (CBA-H), is
also a common type of inpatient screening instrument, which has been used
internationally to discriminate between emotional states and behavioral changes related to
the current hospitalization or health diagnosis (Ceccarini, et al., 2014). Bertolotti,
Sanavio, and Zotti (2002) conducted a validation study for this screening tool in Italian
hospital, and this has since been considered a valid and reliable tool for general
psychological distress screening within the hospital context (Ceccarini, et al., 2014). The
CBA-H is composed by four cards: A, B, C, and D. Card A contains 21 items focusing on
the present time and investigates the emotional state at the time of test completion (i.e.,
hospitalization). Card B contains 23 items asking about the previous three months
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investigating on dysphoria and on other psychophysiological disorders and stress
(Ceccarini, et al., 2014). Card C contains 61 items focusing on the period of time prior to
the disease and it asks a self-reported patient description of his/her stable character and
behavior such as introversion/extroversion, neuroticism, social anxiety, speed and
impatience, job involvement, hostility, hard driving, and irritability (Ceccarini, et al.,
2014). Card D contains 47 items on biographical information about general lifestyle
(work, affective and sexual life, smoking, eating and drinking, sleep quality, and physical
exercise) and health risk factors (Ceccarini, et al., 2014). A limitation to this tool is its
excessive number of questions (Ceccarini, et al., 2014). The questionnaire contains 147
items with a true and false answering system. Also, this tool does not specifically target
the population of cardiac patients, although these patients may be included for screening
(Ceccarini et al., 2014).
A third commonly utilized and studied screening instrument is the Beck
Depression Inventory (BDI-II), which consists of 21 items (Ceccarini et al., 2014). Beck,
Steer, and Brown (1996) developed the screening tool and conducted a validation study,
which showed a strong test-retest reliability for this tool (Ceccarini et al., 2014). The
Beck depression tool assesses the severity of 21 depression symptoms rated on a 4-point
scale (0-3). The tool consists of 13 items which address cognitive or affective symptoms,
and the remaining 8 items assess somatic symptoms such as insomnia and fatigue. BDI
total scores of 10-18 are consistent with mild depression, 19-29 with moderate
depression, and 30 or higher with severe depression (Ceccarini, et al., 2014). The tool has
been supported by a consistent number of studies, and it is known to correspond with
over 90% of clinical diagnoses for patients who suffer from depression (Ceccarini, et al.,
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2014). However, it must be noted that this tool can only be used to measure the severity
of depression and is not necessarily utilized as a diagnostic tool (Ceccarini, et al., 2014).
This limits its use to a measurement of depressive symptoms, and it leaves the provider to
make the initial diagnosis through other means.
Lastly, there is a screening instrument for depression in cardiac patients which is
considered the gold-standard of screening tools in this population of patients (Ceccarini,
et al., 2014). This tool is known as the Patient Health Questionnaire (PHQ-2 and PHQ-9).
The American Heart Association (AHA) recommends using the Patient Health
Questionnaire (PHQ-2) at minimum (Lichtman, et al., 2008). This tool provides two
questions that are recommended for identifying currently depressed patients, and if
positive on either or both questions, it is recommended that all nine PHQ items (PHQ-9)
be asked (Lichtman, et al., 2008). The PHQ-9 is based directly on DSM-IV diagnostic
criteria for major depression, and this tool has shown to be valid and reliable after having
been widely utilized in studies with cardiac patients (Stafford, Hons, Berk, & Jackson,
2007). One study by Stafford, et al., (2007) investigated the validity of the PHQ
instruments relative to a referent diagnostic standard in recently hospitalized patients with
CAD. Three months post-discharge for a cardiac admission, 193 CAD patients completed
the PHQ-9 (Stafford, et al., 2007). The Mini International Neuropsychiatric Interview
(MINI) was the criterion standard (Stafford, et al., 2007). In this study, scale reliability
was calculated using Cronbach's α. Convergent validity was computed using Pearson's
intercorrelations (Stafford, et al., 2007). The internal consistencies for the self-report
questionnaire were excellent with Cronbach's α coefficient of 0.90 for the PHQ-9
(Stafford, et al., 2007). The questionnaire was found to have a sensitivity of 81.5% and a
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specificity of 80.6% (Stafford, et al., 2007). This brief, sensitive, and specific screening
tool may be completed in less than five minutes by a provider or self-administered by the
patient in the same short time period (Lichtman, et al., 2008). This tool has been shown to
be efficient in the detection of depression, and it may also be used in follow up
assessments after the initial diagnosis has been made which adds to its usefulness in
practice (Lichtman, et al., 2008).
Depression Treatment. Despite the high prevalence rate of major depression and
minor depressive symptoms in cardiac patients and their poor prognosis for survival and
quality of life, comparatively few receive treatment for their depressive disorder
(Mavrides & Nemeroff, 2013, p. 332). There are many reasons for this occurrence,
including under-diagnosis and provider reluctance to initiate treatment due to concerns
about the safety of antidepressant medications, including the potential for medication
interactions or unwanted cardiac adverse effects. According to Sin et al., (2014),
researchers have found that efforts to treat and decrease depressive symptoms may be as
important as treating actual symptoms of cardiovascular disease to enhance functional
status. The treatment of depression in patients with cardiovascular disease has shown to
increase overall survival, and this should be considered by providers caring for patients
with CVD.
The most commonly utilized Pharmacotherapy treatment choices for depression
in patients with cardiovascular disease include sertraline, escitalopram oxalate,
venlafaxine hydrochloride, bupropion hydrochloride (Davidson, Rieckmann, Clemow,
Schwartz, Shimbo, Medina, … Burg, 2010). Short-term treatment of depression with
tricyclic antidepressants (TCAs) is relatively safe in patients with cardiovascular disease;
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however, long-term treatment has not been well studied, and orthostatic hypotension is a
serious complication observed with some TCAs (Davidson, et al., 2010). Therefore,
TCAs should be used cautiously in patients with cardiovascular disease, especially those
with baseline postural systolic blood pressure reductions (Davidson, et al., 2010).
Bupropion has been found to be safe in patients with cardiovascular disease although
more studies are needed for this treatment (Davidson, et al., 2010).
One systematic review of randomized control trials found that there is
considerable evidence that antidepressants, especially SSRIs, are safe in the treatment of
major depression in patients with CVD (Mavrides & Nemeroff, 2013). This was a
systematic review of 61 randomized controlled clinical trials retrieved from the databases
PubMed and PsycINFO (Mavrides & Nemeroff, 2013). No trials were excluded, and the
studies included were primarily from North America and Europe (Mavrides & Nemeroff,
2013). The studies contained in this review are randomized control clinical trials, and this
helps to minimize threats to internal validity (Mavrides & Nemeroff, 2013). In this
review, 7 clinical trials of tricyclic antidepressants (TCAs), one of TCAs and bupropion
together, were included, and 10 clinical trials of selective serotonin reuptake inhibitors
(SSRIs) were included as well (Mavrides & Nemeroff, 2013). This review’s results were
consistent across all studies, thereby increasing the generalizability of the results to the
general population of patients with cardiovascular disease.
Raskind et al. (1982) studied 12 men with ischemic heart disease, post-MI and
CABG, who met criteria for secondary major depression, defined as depression that
follows a major illness (Mavrides & Nemeroff, 2013). The goals were to evaluate
changes in cardiac conduction, frequency of orthostatic hypotension, and the efficacy of
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the antidepressant imipramine (Mavrides & Nemeroff, 2013). The authors of this study
concluded that imipramine was safe in a patient with stable ischemic heart disease and
minimal conduction defects; however, if a person had pretreatment orthostatic
hypotension, the frequency of orthostatic hypotension with imipramine should be
considered and prescribed cautiously (Mavrides & Nemeroff, 2013). Imipramine and
doxepin were evaluated by Veith et al. in a randomized, double-blind, placebo-controlled
trial of 24 patients, of whom 23 had experienced an MI, 8 had coronary artery bypass
graft (CABG) surgery, one had a pacemaker, and one had a prosthetic heart valve
(Mavrides & Nemeroff, 2013). The purpose of the study was to evaluate the effects of
imipramine and doxepin on cardiac conduction and determine the antidepressant efficacy
in depressed patients with cardiac disease (Mavrides & Nemeroff, 2013). Veith et al.
concluded that post-MI patients could safely be treated with either imipramine or
doxepin, though if they are at risk for developing orthostatic hypotension, they should
receive alternative treatments (Mavrides & Nemeroff, 2013).
Glassman et al. (1983; 2011) evaluated the use of imipramine in depressed
patients with left ventricular impairment in a prospective trial with 15 depressed patients
undergoing radionuclide angiography (Mavrides & Nemeroff, 2013). Patients received
imipramine and the dose gradually increased to 3.5 mg/kg/day over the course of 3
weeks; the radionuclide angiography was then repeated (Mavrides & Nemeroff, 2013).
Only 11 of the 15 patients completed the entire 3-week treatment period because of
adverse effects (Mavrides & Nemeroff, 2013). Of those who completed the treatment
period, imipramine was reported to be effective in treating the depressive symptoms,
though no information was provided regarding how this was assessed and measured
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(Mavrides & Nemeroff, 2013). Glassman et al. concluded that although imipramine does
not affect ventricular function, orthostatic hypotension was clinically significant and
clearly needs to be monitored (Mavrides & Nemeroff, 2013).
In a similarly designed study, Roose et al. (1986) evaluated the effects of
nortriptyline in 21 depressed patients with decreased left ventricular ejection fraction
(Mavrides & Nemeroff, 2013). The authors suggested that nortriptyline might be a safe
medication for the treatment of depression in patients with heart failure (Mavrides &
Nemeroff, 2013). Roose et al. conducted another trial comparing imipramine (3.5
mg/kg/day) and nortriptyline (1.4 mg/kg/day) in 196 depressed patients with cardiac
conduction disease (Mavrides & Nemeroff, 2013). The patients were enrolled for over 10
years (Mavrides & Nemeroff, 2013). Both nortriptyline and imipramine were found to be
effective antidepressants, with nortriptyline causing less cardiac side effects (Mavrides &
Nemeroff, 2013). The authors concluded that in patients with cardiac conduction deficits,
with or without heart failure, nortriptyline is preferable to imipramine (Mavrides &
Nemeroff, 2013). Dietch et al. (1987) studied 10 elderly, depressed patients with cardiac
conduction disease treated with nortriptyline with the primary goal to evaluate EKG
changes associated with the medication (Mavrides & Nemeroff, 2013). Each patient had
abnormal EKGs at baseline, with first-degree AV block, hemi-blocks, bundle branch
blocks, and bradycardia (Mavrides & Nemeroff, 2013). Nortriptyline was effective in
treating depressive symptoms of elderly patients and was associated with minimal risk in
patients with conduction disease (Mavrides & Nemeroff, 2013).
Cohen et al. (1993; 2010) evaluated trimipramine in an open study of 22 patients
with mild heart disease and mild to moderate depression in a 28-day trial (Mavrides &
27

Nemeroff, 2013). Depression severity was assessed using the CGI Scale and Hamilton
Depression Scale (HAM-D). The goal of the trial was to evaluate the efficacy of
trimipramine and monitor cardiac changes and adverse effects (Mavrides & Nemeroff,
2013). Trimipramine seemed to be safe and effective for depression in patients with mild
heart disease (Mavrides & Nemeroff, 2013). Roose et al. compared the effects of
imipramine and bupropion in depressed patients with heart failure in a double-blind
crossover study, which was comprised of 10 patients (Mavrides & Nemeroff, 2013).
Bupropion and imipramine were equally efficacious in the treatment of depression
(Mavrides & Nemeroff, 2013). The authors concluded that bupropion was safer than
imipramine for use in depression accompanied by heart failure secondary to the low
frequency of orthostatic hypotension and negligible effects on left ventricular function
(Mavrides & Nemeroff, 2013).
A small double-blind, randomized, controlled 6-week trial comparing paroxetine
to nortriptyline in 81 patients with both depression and ischemic heart disease assessed
the efficacy and cardiovascular safety of the two medications (Mavrides & Nemeroff,
2013). Although paroxetine and nortriptyline were both effective antidepressants,
nortriptyline was associated with significantly more frequent and serious cardiac events
than paroxetine (Mavrides & Nemeroff, 2013). Roose and colleagues used a historical
control group to compare the potential cardiovascular effects of fluoxetine and
nortriptyline, 27 patients received the SSRI and 60 patients received the TCA (Mavrides
& Nemeroff, 2013). Although this was a historical controlled non-prospective trial,
fluoxetine did not exhibit the cardiovascular side effects that were observed with
nortriptyline (Mavrides & Nemeroff, 2013).
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Additional evidence from a clinical trial that SSRIs might be beneficial and safe
in cardiac patients came in 1999, when Shapiro et al. performed an open-label study
evaluating the safety, tolerability, and efficacy of sertraline in post-MI patients in the
Sertraline Antidepressant Heart Attack Trial (SADHAT). Sertraline led to improvement
in depressive symptoms without any increased risk of adverse cardiac events. Further
evidence of the potential efficacy of SSRIs in CVD patients came from a double-blind,
placebo-controlled trial of fluoxetine (Mavrides & Nemeroff, 2013). In this 25-week
study, 54 patients with depression and recent MI were enrolled (Mavrides & Nemeroff,
2013). The authors concluded that fluoxetine is a safe and effective antidepressant in
patients who are post-MI (Mavrides & Nemeroff, 2013). Further evidence for the efficacy
of SSRIs in depressed patients with cardiac disease is derived from the Canadian Cardiac
Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) study.
This 2 × 2 factorial designed trial evaluated the efficacy of IPT and citalopram in 284
patients with CAD over a 12-week period (Mavrides & Nemeroff, 2013). Surprisingly,
some of the subgroup analyses suggested that clinical management may be more effective
than IPT in patients with low baseline social support or poor day-to-day functioning
(Mavrides & Nemeroff, 2013).
Two large multicenter trials, ENRICHD and MINDIT assessed the treatment of
depression in patients with MDD and CAD. In the ENRICHD trial (Enhancing Recovery
in Coronary Heart Disease), 2,481 patients with acute MI and major depressive disorder,
minor depressive disorder, or dysthymia were randomized to CBT or treatment as usual
(Mavrides & Nemeroff, 2013). The group receiving CBT showed a small but statistically
significant decrease in their depressive symptoms, but exhibited no change in the
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incidence of cardiac events during the initial 6-month treatment period. In MIND-IT
(Myocardial Infarction Depression Intervention Trial), 91 post-MI depressed patients
were randomized to receive either mirtazapine or citalopram. Patients were followed for
an average of 27 months (Mavrides & Nemeroff, 2013). The antidepressant efficacy of
mirtazapine and citalopram was not superior to placebo (Mavrides & Nemeroff, 2013).
Interestingly, patients who did not respond to antidepressant treatment exhibited a higher
rate of cardiac events when compared to those who responded to the antidepressant
(Mavrides & Nemeroff, 2013).
In the SADHART-CHF trial, O’Connor et al. studied the antidepressant efficacy
and cardiovascular safety of sertraline versus placebo in depressed patients with CHF.
This was a 12-week randomized, double-blind, placebo-controlled trial (Mavrides &
Nemeroff, 2013). Depression symptom severity was rated using the HAM-D, and patients
were treated with sertraline (50–200 mg/day) or placebo in addition to nurse-facilitated
support (Mavrides & Nemeroff, 2013). Of the 469 patients enrolled, 234 patients
received sertraline and 235 patients received placebo. Sertraline was not superior to
placebo (P = 0.89, 95% CI −1.7 to 0.9), though both groups exhibited a statistically
significant reduction in HAM-D scores (P < 0.001). A significantly larger number of
subjects in the sertraline group withdrew from the study due to medication side effects
(27/234; 11.5%) compared to the placebo group (14/235; 6%; P = 0.03). There was no
statistically significant difference in all-cause mortality between the groups (Mavrides &
Nemeroff, 2013). The authors concluded that sertraline neither improved depression nor
cardiac outcomes compared to placebo (Mavrides & Nemeroff, 2013). One of the
possible limitations of the study was the relatively moderate severity of depression of the
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patients that comprised the study (HAM-D scores were 19.9 in the sertraline group and
18.4 in placebo).
As concluded by Mavrides and Nemeroff (2013) in their systematic review,
selective serotonin reuptake inhibitors (SSRIs) are considered to be the safest of the
antidepressants for these patients with cardiovascular disease, and this class of
antidepressants is associated neither with orthostatic hypotension nor conduction
abnormalities (Mavrides & Nemeroff, 2013, p. 339). Furthermore, multiple randomized
clinical trials have demonstrated that two SSRI antidepressants, sertraline and citalopram,
are the safest for patients with cardiovascular disease and are effective for moderate,
severe, or recurrent depression in this population of patients (Mavrides & Nemeroff,
2013; Lichtman et al., 2008). This study is Level I Evidence with an excellent quality
rating (A) (Dearholt & Dang, 2012).
Depression Education for Patients, Families, and Interdisciplinary Team.
One pilot study with a randomized controlled design evaluated psychosocial support and
the effect of interdisciplinary team education for post-cardiac surgery heart failure
patients (Agren, Berg, Svedjeholm, & Stromberg, 2014). The study included a total of 42
patient-partner completed baseline assessments for evaluating psychosocial support and
education from an interdisciplinary team approach. Patients with postoperative health
failure and their partners were chosen to participate in 3 month and 12 month follow up
phone interviews (Agren et. al., 2014). Randomization was performed using a randomnumber table with block of 12 (Agren et. al., 2014). Several questionnaires were used,
including a demographic questionnaire, Charlson Comorbidity Index, SF-36, Beck
Depression Inventory, and Perceived Control (Agren et. al., 2014). Partners in the
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intervention group increased health in the role emotional and mental health dimensions,
and patients increased health in vitality, social function, and mental health dimensions as
compared with the control group (Agren et. al., 2014). Patients’ perceived control
improved significantly in the intervention group over time (Agren et. al., 2014). The
results of this study suggest that psychoeducational support from a multidisciplinary team
to post-cardiac surgery heart failure dyads (patient and partner) improves health and
perceived control in patients after 3 and 12 months (Agren et. al., 2014). These results
also suggest that interventions focusing on psychoeducational support can improve the
life situation for the patient-partner and especially for the patients (Agren et. al., 2014).
Psychoeducational support appears to be a promising intervention, but the results need to
be confirmed in larger studies (Agren et. al., 2014). One limitation to this study is the
relatively small sample of couples in the study, which poses a threat to external validity.
There were also some inter-group differences and outcomes, which would limit
generalizability. This study is Level I Evidence with a good quality rating (B) (Dearholt
& Dang, 2012).
2.3 Synthesis of Literature
According to Melnyk and Fineout-Overholt (2015) synthesis is not a
summarization of the articles identified as significant, but it is rather a process of critical
thinking built on several principles of the synthesis. After a comprehensive analysis of
the literature was performed, inferences were made to synthesize best practices for
screening for depression in patients with cardiovascular disease. Major depressive
disorder and depressive symptoms are prevalent in the population of patients with
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cardiovascular disease, especially those who have recently been hospitalized for a cardiac
event (Peters, et al., 2010).
Timely screening, detection, and treatment of depression in patients with
cardiovascular disease may help to improve quality of life and increase overall survival
for these patients (Sin, et al., 2014). Although screening tools have been condensed and
are readily available to providers in primary care practices for their patients, synthesis of
the literature has shown that screening for depression in CVD patients is not routinely
undertaken in any setting, inpatient or outpatient (Lichtman, et al., 2008; Peters, et al.,
2010; Ceccarini, et al., 2014). Through comparison of the available depression screening
tools, synthesis of the literature revealed that the PHQ-2 and PHQ-9 tools are the most
brief, sensitive, and specific depression screening tool for patients with cardiovascular
disease (Ceccarini, et al., 2014; Mavrides & Nemeroff, 2013). Since the PHQ
questionnaire can be easily self-administered by patients or by the healthcare provider in
5 minutes or less, this tool is also considered the most time efficient of the depression
screening tools (Ceccarini, et al., 2014). The PHQ questionnaire is also recommended by
AHA as the most appropriate screening for this population of patients (Lichtman, et al.,
2008). Providers should be prepared to treat and refer these patients based on results of
the individual screenings. Multiple safe treatment options exist for patients who test
positive for depressive symptoms, and the provider should weight benefits and risks
when deciding upon appropriate treatment regimens in patients with depression who have
cardiovascular disease (Davidson, et al., 2010; Mavrides & Nemeroff, 2013). Overall,
there is good evidence to implement the use of PHQ depression screening for
cardiovascular patients in primary care.
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2.4 Recommendations
Based on the evidence illustrated from the selected studies in this review,
recommendations have been identified to assist primary care providers in improving the
quality and timeliness of care delivered to cardiovascular patients who are suffering from
depression. These recommendations have been graded according to Dearholt & Dang’s
(2012) book John Hopkins Nursing Evidence-Based Practice: Model and Guidelines.
The recommendations have been based on the quality and amount of evidence available
to support the implications for guidelines, practice parameter, or clinical policy.
1. Screening for Depression in Patients with CVD – Grade A (High Quality)
Evidence. Psychological distress has a significant negative impact on patients
with CVD and is often under-recognized by health care providers (Lichtman et
al., 2008). Primary care providers and cardiovascular specialty providers are
called upon to improve their recognition of psychological distress in their patients
and assure referrals are made to collaborative care teams for proper diagnosis and
treatment (Lichtman et al., 2008). At a minimum, the Patient Health
Questionnaire (PHQ-2) provides two questions that are recommended for
identifying currently depressed patients. If the answer is “yes” to either or both
questions, it is recommended that all nine of the PHQ items (PHQ-9) be asked
(Lichtman et al., 2008). For patients with mild symptoms, follow-up during a
subsequent visit is advised at which time the PHQ-9 questionnaire may again be
utilized for screening. In patients with positive depression scores, a provider or
nurse should review the answers with the patient, and treatment options should be
discussed with the patient (Lichtman et al., 2008).
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2. Treatment of Depression in Patients with CVD – Grade A (High Quality)
Evidence. There is considerable evidence from randomized controlled clinical
trials that antidepressants, especially SSRIs, are safe in the treatment of major
depression in patients with CVD (Mavrides & Nemeroff, 2013). Researchers have
concluded that frequent and timely treatment adjustment by primary care
physicians, along with increased patient self-monitoring, improved control of
diabetes, depression, and heart disease (Mavrides & Nemeroff, 2013). Evidence
also suggests that depressed patients who are not responsive to treatment for
depression may be at greater risk for adverse cardiac events, but aggressive
cardiologic care may help mitigate this increased risk. Depressed patients may
also require additional clinical management to ensure compliance with cardiac
treatment regimens and to promote lifestyle behavior change (Lichtman et al.,
2008).
3. Provide education to the providers, staff, patients, and family members –
Grade B (Good Quality) Evidence.
Formal and clear procedures, mechanisms, regular case reviews, and peer staff
development need to be in place in order to sustain a successful screening
program and offer an environment which aids in bringing about the best outcome
for the patient dealing with depression. Psychoeducational intervention has been
found to reduce anxiety and depression in patients with cardiovascular disease,
and educational interventions increase family satisfaction (Agren et. al., 2014).
When the families and the patients are well-informed, there is a basis for fruitful
and effective communication between them and the healthcare professionals
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leading to increased compliance to treatment regimens and overall better
outcomes (Agren et al., 2014).
2.5 Chapter Summary
Despite the devastating consequences, comorbid cardiovascular disease and
depression remain poorly recognized and treated (Paz-Filho, 2010; Lichtman et al.,
2008). Primary care providers and cardiovascular specialty providers are called upon to
improve their recognition of depression in their patients and assure referrals are made to
collaborative care teams for proper diagnosis and treatment (Lichtman et al., 2008).
There is a vast literature on depression in cardiovascular patients, and this review has
analyzed some of that literature and synthesized recommendations for providers in
primary care practices with the purpose of standardizing routine screening for depression
in cardiovascular patients in primary care. Based on the evidence, recommendations
include screening for and treatment of depression in these patients, as well as
recommendations for provider, staff, patient, and family education throughout the
screening and treatment processes (Lichtman et al., 2008; Mavrides & Nemeroff, 2013;
Agren et. al., 2014).
With regard to screening tools, the PHQ-2 and PHQ-9 questionnaires are the most
brief, sensitive, and specific depression screening tool for patients with cardiovascular
disease (Ceccarini, et al., 2014; Mavrides & Nemeroff, 2013). The PHQ-9 is based
directly on DSM-IV diagnostic criteria for major depression, and this tool has shown to
be valid and reliable after having been widely utilized in studies with cardiac patients
(Stafford et al., 2007). Multiple safe treatment options exist for patients who test positive
for depressive symptoms with SSRIs being shown as especially safe and effective in
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patients with cardiovascular disease (Davidson, et al., 2010; Mavrides & Nemeroff,
2013). Also, recommendations have been made for further research into this area of study
in order to support standardized screening protocols that might facilitate improved
processes for patients with depression with cardiovascular disease in all primary care
settings (Huffman et. al., 2014).
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Chapter 3 Methodology
3.1 Introduction
According to the American Heart Association (2016), there is no goldstandardized procedure for screening for depression in cardiovascular patients. Screening
for depression varies greatly across specialties and practices, often leaving a gap for
detection and treatment of depression in cardiac patients (McGuire et al., 2015). The
purpose of this project is to determine the best screening depression tool and implement
the tool for early detection of depression in primary care settings for patients with
cardiovascular disease. The purpose of this chapter is to describe the design, sample,
setting, depression screening tool, and procedures utilized in this project.
3.2 Design
A descriptive pre-test and post-test survey design will be conducted to compare
findings from two primary care settings, which use the Patient Health Questionnaire
(PHQ) depression screening tool to screen for depression in cardiovascular patients. The
PHQ is a multiple-choice self-report inventory used for screening and diagnosing
depression. It is copyrighted by Pfizer Inc.
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3.3 Unit of Analysis
The first unit of analysis will include the findings from an audit on 60 patient
charts and the results of their depression screenings. Demographic data that will be
collected includes age, gender, and race of all the patients.
The second unit of analyses will include data from the Patient Health
Questionnaire (PHQ). The tool is available in two forms, PHQ-2 and PHQ-9. The PHQ2 comprises the first two questions in the PHQ-9 questionnaire. As McGuire, et al.,
(2015) discusses, the PHQ-2 screening scale is the best brief screening instrument for use
during a routine visit intake or annual physical examination survey. According to the
American Psychological Association (2016), the PHQ-2 inquires about the degree to
which an individual has experienced a depressed mood and anhedonia over the past two
weeks. Its purpose is not to establish a final diagnosis or to monitor depression severity,
but rather to screen for depression (APA, 2016). Patients who screen positive should be
further evaluated with the PHQ-9 to determine whether they meet criteria for a depressive
disorder (APA, 2016).
The third unit of analysis will include the providers’ demographic data who care
for cardiovascular patients in primary care settings. The providers are employed in family
practice settings located in the Pee Dee area of rural South Carolina. Demographic data
includes one MD and one Family Nurse Practitioner in the first family practice and two
MDs and one FNP in the second family practice. Provider gender, provider specialty, and
provider length of time (years) in practice will be collected for each provider. Providers
will also be asked if they have utilized the PHQ screening tool in practice previously.
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3.4 Sample
The sample includes 60 adult cardiovascular patients who present for primary
care in two primary care settings in rural Pee Dee South Carolina. For the purpose of this
project, a patient with “cardiovascular” disease will be defined as any patient who is 18
years of age or older and has any or a combination of the following diagnoses: coronary
artery disease, stroke, hypertension, congestive heart failure, arrhythmias, valvular heart
disease, cardiomyopathy, myocardial infarction, and rheumatic heart disease. The
primary care providers are adult primary care providers, including three physicians and
two family nurse practitioners. All providers are licensed by the state of South Carolina.
3.5 Setting
The settings include two family practices in rural South Carolina in the Pee Dee
area. The family practices are comprehensive family practices open five days per week,
with on-call after hour services. These practices serve as the patient’s first point of entry
into the health care system and as the continuing focal point for all needed health care
services. The first practice sees an average of 38 patients per day, and the second practice
sees an average of 51 patients per day.
3.6 Outcomes to be measured
The PHQ-9 is a nine-item self-report measure developed to diagnose the presence
and severity of depression in primary care (Stafford, Hons, Berk, & Jackson, 2007). It is
based directly on DSM-IV diagnostic criteria for major depression (Stafford, et al., 2007).
It has the potential of being a dual-purpose instrument that, with the same nine items, can
establish depressive disorder diagnoses using a categorical algorithm and grade the
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depressive symptom severity (Stafford, et al., 2007). As a severity measure, the score on
the PHQ-9 will range from 0 to 27 for each patient. The scale is scored as follows: 1-4
(minimal depression), 5-9 (mild depression), 10-14 (moderate depression), 15-19
(moderately severe depression), and 20-27 (severe depression) (Stafford, et al., 2007).
In multiple studies, PHQ-9 scores greater than 10 have been found to have a
sensitivity of 88% and a specificity of 88% for Major Depressive Disorder (APA, 2016).
The PHQ questionnaires have been shown to be valid and reliable and have been widely
utilized in studies with cardiac patients (Stafford, et al., 2007). The Mini International
Neuropsychiatric Interview (MINI) was the criterion standard (Stafford, et al., 2007). In
this study, scale reliability was calculated using Cronbach's α. Convergent validity was
computed using Pearson's intercorrelations (Stafford, et al., 2007). The internal
consistencies for the self-report questionnaire were excellent with Cronbach's α
coefficient of 0.90 for the PHQ-9 (Stafford, et al., 2007).
3.7 Framework/model of research: Stetler’s Model
The Stetler model of Evidence-Based Practice (Appendix D) was chosen because
it has long been known as a practitioner-oriented model which utilizes research findings
in order to facilitate safe and effective evidence-based nursing practice (Melnyk &
Fineout-Overholt, 2015). There are five phases in the Stetler model. First, Stetler’s
model will be utilized by ensuring the providers and practices are ready for the change
and systematically conducting a search for relevant evidence (Melnyk & FineoutOverholt, 2015). Stetler’s second phase has been utilized to assess a body of evidence,
summarize the evidence for quality and validity, and identify a need through the
systematic collection of evidence (Melnyk & Fineout-Overholt, 2015). Phase three will
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be used to compare the responses from the survey and evaluate if the intervention
combined with the guidelines proposed a change to current practice. The fourth phase of
Stetler’s model will be used to demonstrate translation or application of the intervention,
with the implementation of the PHQ-2 and PHQ-9 screening tools for patients with
cardiovascular disease (Melnyk & Fineout-Overholt, 2015). In phase five, evaluation of
the plan to improve outcomes for patients with CVD who suffer from depression through
the implementation of screening tools and follow-up screenings with appropriate
treatment will be implemented and evaluated (Melnyk & Fineout-Overholt, 2015).
3.8 Description of intervention
Depression screening is an essential part of the detection, treatment, and referral
of patients with depressive disorders. The PHQ-2, comprising the first 2 items of the
PHQ-9, inquires about the degree to which an individual has experienced depressed
mood and anhedonia over the past two weeks. Its purpose is not to establish final
diagnosis or to monitor depression severity, but rather to screen for depression. Patients
who screen positive on the PHQ-2 should be further evaluated with the PHQ-9 to
determine whether they meet criteria for a depressive disorder.
According to McGuire et al., (2015), there continues to be a significant practice
gap in relation to screening, referral, and treatment of depression in CVD patients (p.
427). Although the American Heart Association recommends routine screening for
depression in patients with cardiovascular disease, there are conflicting opinions among
healthcare providers with regard to timing of screening and location of screening,
especially in cardiology and primary care settings (Kronish, et al., 2012).
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Prior to administering the PHQ screening tool to patients, the providers at both
primary care practices will be given educational handouts that contain information
regarding the PHQ-2 and PHQ-9 depression screening tools. These educational handouts
will include the following: risk factors of depression in patients with cardiovascular
disease, signs and symptoms of depression, directions for utilizing the PHQ tool,
importance of educating patients and families regarding depression, and an algorithm for
initiation of depression treatment and referral for those patients who test positive during
screening.
The providers will also have the opportunity to view a YouTube video describing
the use and administration of PHQ screening for depression. The YouTube video is
presented by Dr. Charles Porter and a Cardiology group in Kansas City on behalf of
patients who have comorbid cardiovascular disease and depression. The video is 4
minutes and 14 seconds in length, and the providers may easily view the video from
home. The video may be accessed via the following URL:
https://www.youtube.com/watch?v=DtQCp5350as. A sign in sheet will be provided at
the offices for providers to sign once they complete the video. These additional resources
will allow each provider equal opportunity to access significant information regarding
depression screening in cardiovascular patients.
3.9 Strategies to reduce barriers and increase supports
The influential change participants in primary care will include practice
administrators, board of directors, and primary care providers. In order for the
implementation of these screenings to be successful, support of these influential
participants must be obtained. A strategy that will increase support is to demonstrate the
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ease of use and effectiveness of the short screening PHQ tools. This cost-effective and
easy-to-use tool may be easily administered and has been shown to decrease morbidity
and mortality in patients with cardiovascular disease, thereby reducing healthcare costs.
The PHQ screening tools are a cost-effective, reliable, valid, and time-efficient approach
to improving patients’ quality of life. The strategic process for implementing this
intervention can be addressed with the most significant emphasis on improving quality of
life for patients with cardiovascular disease.
A potential barrier to successful implementation of routine depression screening is
the issue of fidelity. Burns, Grove, and Gray (2013) describe fidelity as the consistent
implementation of an intervention. Since part of the plan will involve other providers, it
will be of utmost importance to ensure that an organized plan or protocol is in place so
that each provider interacts with the patients in the same manner in relation to the project.
The protocol for implementation of this screening tool will require that each patient has
cardiovascular disease and is 18 years of age or older. The protocol will require that the
first two questions of the tool (PHQ-2) be administered to the patient by the provider
while the provider is in the room to examine the patient. If these two questions are
positive, the provider will proceed by administering the remaining seven questions of the
questionnaire. The protocol will then require that the provider score the patient’s
depression according to the scale that is provided with the PHQ tool. If the patient is
tested positive for depression, the provider will be asked to document in chart the
implemented treatment plan, follow up, education, and any referrals that are made. This
protocol will be discussed with each provider and will be given as a handout prior to
implementation of the screening tool.
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If the screening tool is to be implemented into the EMR for future implementation
of this tool into project, this may limit the feasibility utilization of the screening tool since
EMRs have been traditionally difficult to change or manipulate. There has also been
consideration concerning administration of the PHQ-2 and PHQ-9 screenings on paper
and having them scanned into the EMR since the providers are still using some paper
forms in conjunction with EMR documentation. As Melnyk and Fineout-Overholt (2015)
discuss, many times it takes more time to carry out a study than is projected in the
beginning of the project. Time is also a possible limit to administration of screenings and
collection of data, but it is hopeful that the project may be undertaken as a 3-month
review of the initial screenings and initial follow up visits without difficulty.
3.10 Instruments
Provider demographic information will be collected during a scheduled office
visit and entered into Microsoft Excel for analysis comparison using the Data Analysis
Tool. Similarly, during the chart audits, each patient’s demographic data will be collected
and entered into the Data Analysis Tool in Microsoft Excel. Demographic data for
patients will include age, gender, and race. The PHQ screening tool will be administered
to the patients by the provider. The PHQ screening tool will be administered on paper and
scanned into the electronic medical record for review at the end of the 3-month period.
3.11 Procedure
Step one will consist of training the providers on the use of the tool and
administration of the tool. The PHQ depression screening tool will be administered by the
providers to the patients in the privacy of the examining room if the patient meets
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appropriate criteria and agrees to the screening. Patients must be 18 years or older and
must have a documented history of cardiovascular disease without a documented history
of depression. The PHQ-2 will be answered, which consists of the first two questions of
the scale. If positive, the remaining seven questions (PHQ-9) will be administered.
Copies of the PHQ tool will be given to both practices. Completed tools will be scanned
into the EMR in each respective patient’s chart. If the patient self-identifies that they are
moderately or severely depressed based on a score of 10 or higher on the PHQ scale, then
the patient is referred for further assessment and intervention.
After the University of South Carolina Institutional Review Board (IRB) approves
the study, the quality improvement project will commence. Educational handouts
regarding the importance of depression screening in cardiovascular patients and regarding
the use of PHQ screening tools will be given to the providers at enrollment into this
project. The handouts will contain information on signs and symptoms of depression that
have been commonly encountered by cardiac patients. The handouts will identify the
importance of educating patients and family members regarding the seriousness of
depression and the availability of treatment. Providers will be provided with email and
phone number in order to ask any questions regarding implementation of the screening
tool for this project.
Three months after implementation of the PHQ screening tool, 60 charts will be
reviewed, which will include a total of 30 charts from each practice. Data obtained from
the PHQ tools will be migrated into Microsoft Excel’s for statistical and descriptive
analysis of the Likert scale. Each question (Appendix C) will be calculated by the mode.
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The mode of the data is the value which appears most frequently as mentioned
previously. This will be placed in a table and illustrated in a bar graph format.
3.12 Protection of Human Subjects
The Collaborative Institutional Training Initiative (CITI) course on protection of
human subjects will be completed by the investigator for the University of South
Carolina prior to data collection. Two members of the committee will provide scientific
review of the proposal. Since this project includes research of medical records, review
and approval by the University of South Carolina’s IRB will be required. IRB approval
for this project will be sought prior to any involvement of patient information. The
investigator is an employee of the healthcare system in which the practices are included
and has access to the electronic medical records.
Once the committee and IRB have reviewed and approved the project, the
investigator will begin data collection. Only essential patient data for the project will be
retrieved. Data that will be retrieved from each chart are as follows: age of the patient,
race, gender, cardiovascular diagnoses, existence of previous psychiatric diagnoses,
PHQ-2 and PHQ-9 screening results, subsequent initiation of depression treatment and
counseling by the providers, and initiation of psychiatric referrals if needed.
All data which is collected will be saved in the investigator’s computer in a
password protected spreadsheet. The computer to be utilized is password protected, and
there will be no record included to identify any of the subjects. The patients will be
assigned a number as a patient identifier, and their names will not be used. In order to
protect patient information, all patient information will be collected, encrypted, and
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stored on a flashdrive. No tracers will be linked to patient health records in order to
protect patient anonymity.
3.13 Data Analysis Methods
PHQ screening tool results of 60 patients with cardiovascular disease will be
collected during chart review and entered into Microsoft Excel. The Data Analysis tool in
Excel will be utilized to graphically display the results of the PHQ screenings. Microsoft
Excel spreadsheets and graphs will also be utilized for collection of the providers’
demographic data. Excel Data Analysis Correlation function will be utilized to compare
provider usage of the tool between the two practices, which will allow for inferences to
be made regarding provider demographic data and use of PHQ screening tools between
the two practices.
Once the survey data is entered into the Excel spreadsheet and the identifiers
removed, the data will be reviewed and organized in collaboration with a University of
South Carolina statistician. Data analyses will include both descriptive and inferential
statistics using the Data Analysis tool in Excel.
3.14 Chapter Summary
Despite poor outcomes, comorbid cardiovascular disease and depression remain
poorly recognized and treated. Primary care providers are called upon to improve their
recognition of depressive symptoms in their patients and assure appropriate treatment is
initiated per current guidelines. At new patient and routine follow up visits, the PHQ-2
and PHQ-9 screening tools should be implemented for each patient who has
cardiovascular disease. This active approach to delivering quality care and screening for
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prevention of complications from depression can potentially improve quality measures
and outcomes in management of patients with cardiovascular disease.
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Chapter 4 Results
4.1 Introduction
According to Lichtman, et al., (2008), there is a high prevalence of depression in
patients with cardiovascular disease. Thus, the American Heart Association (2016) has
recommended routine screening for depression. In this DNP quality improvement project,
a descriptive pre-test and post-test survey design was conducted to compare findings
from two primary care settings that implemented the use of the brief and efficient Patient
Health Questionnaire (PHQ) depression screening tool to screen for depression in
cardiovascular patients. The purpose of this chapter is to present the findings with a
discussion.
4.2 Description of Sample
Out of the sixty patient charts which were audited, fifty-one (response rate was
85%) patient health questionnaire (PHQ) depression screening tool surveys were
completed. These questions were administered to the patients by five primary care
providers in two primary care practices in the Pee Dee area over a two-month period. The
primary care providers are adult primary care providers, including three physicians and
two family nurse practitioners. All providers are licensed by the state of South Carolina.
The patients were screened for depression through use of the PHQ-2 and PHQ-9
depression screening tools. Thirty charts were initially audited from each practice. Five
patients canceled their appointments prior to screening, three patients did not show for
their appointments, and one patient declined to answer the screening survey questions.
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There were twenty-three patients who answered the screening tool survey questions from
the first practice, and twenty-eight patients responded to the survey in the second primary
care practice. The final sample (n = 51) was comprised of adult patients, ages ranging
from 35-78, who had a pre-existing cardiovascular diagnosis but no history of diagnosed
depression. Cardiovascular diagnoses for these patients included hypertension, coronary
artery disease, history of myocardial infarction, congestive heart failure, and stroke.
4.3 Analysis of Research Questions
Table 4.1 depicts the frequency distribution of the patients’ responses to the
depression screening tool survey from both practices combined. Microsoft Excel’s
FREQUENCY function for data analysis was utilized to calculate frequency
distributions. According to the screening tool results, 29% (n=15) of the sample
population had little interest or pleasure in doing things over the past 2 weeks. Results
also indicated that the patients felt down or depressed over the 2 weeks prior to screening.
Following the initial two questions of the surveys, trouble sleeping (27%) was the next
most common symptom identified. (Table 4.1).
Table 4.2 depicts the comparison of patients’ responses between the two primary
care practices. Responses were similar from both practices. None of the sample had a
formalized diagnosis of depression or treatment of depression prior to implementation of
this screening tool. Of note, Practice 1 had a higher rate of positive responses to trouble
concentrating, moving or speaking slowly, and restlessness. However, these patients from
Practice 1 also had prior diagnoses of attention deficit disorders. The patients were not
currently receiving treatment for attention deficit disorders (Table 4.2).
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Table 4.1 PHQ Screening Tool Survey Frequency Distributions (Both Practices)
Over the past 2 weeks, have you been bothered
by any of the following?

Little interest or pleasure in doing things
Feeling down, depressed, or hopeless
Trouble falling asleep, staying asleep, or sleeping
too much
Feeling tired or having little energy
Poor appetite or overeating
Feeling bad about yourself, that you are a failure,
or that you have let yourself or your family down
Trouble concentrating on activities such as
reading the newspaper or watching television
Moving or speaking so slowly that other people
could have noticed, or being so fidgety or restless
that you have been moving around a lot more
than usual
Thinking that you would be better off dead or that
you want to hurt yourself in some way

Yes

No

%
29
29
27

%
71
71
-

23
18
20

-

22

-

12

-

4

-

Table 4.3 depicts the t-Test calculations which were performed utilizing the Data
Analysis TookPak with t-Test function in Microsoft Excel. Results showed that there
were no statistically significant differences between the practices for patients reporting
depression symptoms using the PHQ. Patients with cardiovascular disease reported
depression symptoms across the board in both practices (Table 4.3.)
Table 4.4 depicts the prevalence of each category of depression severity from
both practices as diagnosed from utilization of the PHQ screening tool. Providers were
able to make diagnosis with severity of depression using the results of the PHQ
screenings. The majority of patients in each practice scored 10-19 on the PHQ scale
which indicated that these patients were in the severity categories of “moderate”
depression or “moderately severe” depression per the PHQ scoring card. (Table 4.4).
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Table 4.2 Comparison of PHQ Results Between Two Primary Care Practices
Over the past 2 weeks, have you been
bothered by any of the following?

Practice 1
“Yes” Responses

Practice 2
“Yes” Responses

Little interest or pleasure in doing things

%
26

%
32

Feeling down, depressed, or hopeless

26

32

Trouble falling asleep, staying asleep, or
sleeping too much

26

29

Feeling tired or having little energy

21

25

Poor appetite or overeating

17

18

Feeling bad about yourself, that you are a
failure, or that you have let yourself or your
family down

22

18

Trouble concentrating on activities such as
reading the newspaper or watching television

26

18

Moving or speaking so slowly that other
people could have noticed, or being so fidgety
or restless that you have been moving around
a lot more than usual

17

7

Thinking that you would be better off dead or
that you want to hurt yourself in some way

4

4
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Table 4.3 t-Test Values of Comparison of PHQ Results Between Practices
t-Test: Two-Sample Assuming Equal Variances

Practice 1

Practice 2

Mean

20.55555556

20.33333333

Variance

52.52777778

103.75

9

9

Observations
Pooled Variance

78.13888889

Hypothesized Mean Difference

0

df

16

t Stat

0.053328593

P(T<=t) one-tail

0.479065139

t Critical one-tail

1.745883676

P(T<=t) two-tail

0.958130278

t Critical two-tail
2.119905299
Table 4.4 Depression Severity in Patients with CVD as
Compared Between Two Primary Care Practices
Depression Severity
Practice 1
Practice 2
%
%
Mild Depression
33
22
Moderate Depression

50

33

Moderately Severe Depression

0

33

Severe Depression

17

11

Table 4.5 compares the implementation results of the two practices for the
cardiovascular patients who tested positive for depression. Consistent with current
literature, the most commonly chosen antidepressants for the patients were the SSRIs
sertraline and escitalopram (Davidson, et al., 2010). SSRIs were chosen most frequently
(50% of patients with positive diagnosis) above all other antidepressants in Practice 1 and
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in Practice 2 (67%). Bupropion was the second choice after SSRIs in both practices.
There was one patient in each practice who answered “yes” to the question regarding
thoughts of self-harm, and these two patients were referred immediately for psychiatric
evaluation and counseling.
Table 4.5 Comparison of Depression Treatment Interventions Between Two
Practices
Interventions utilized by the primary care
Practice 1
Practice 2
providers for treatment of depression
%
%
Initiation of SSRI (sertraline, escitalopram,
50
67
citalopram)
Initiation of SNRI (venlafaxine)

17

11

Initiation of Bupropion

33

22

Initiation of Tricyclic Antidepressants

0

0

Depression Counseling

100

100

Referral to Psychiatry

17

11

Table 4.6 depicts the t-Test calculations which were performed utilizing the Data
Analysis TookPak with the t-Test function in Microsoft Excel. The p-value
(0.964134897) for these results was not statistically significant. The providers in both
practices utilized similar treatment approaches for these patients based on current
evidence-based depression treatment recommendations and guidelines. (Table 4.6.)
4.4 Conclusion
Frequency distributions were calculated for PHQ depression screening survey
results for each question in order to note the frequency of depressive symptoms in this
sample of patients with cardiovascular disease. Patients who answered “yes” to the initial
two screening questions were asked the remaining seven questions per the screening tool
guidelines. Results were then compared between the two practices to note differences in
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patients’ responses from each practice.
Table 4.6 t-Test Values of Comparison of Treatment Choices Between Practices
t-Test: Two-Sample Assuming Equal Variances
Practice 1
36.16666667
1263.766667
6
1411.366667
0
10
0.046104222
0.482067449
1.812461123
0.964134897
2.228138852

Mean
Variance
Observations
Pooled Variance
Hypothesized Mean Difference
df
t Stat
P(T<=t) one-tail
t Critical one-tail
P(T<=t) two-tail
t Critical two-tail

Practice 2
35.16666667
1558.966667
6

After frequency distributions were calculated, it was noted that 29% of the sample
population had depressive symptoms. This data is consistent with the evidence-based
literature that demonstrates that patients with cardiovascular disease are at high risk for
depression and should be routinely screened for depression in their primary care homes
as recommended by the American Heart Association (2016). Each of these patients
(n=15) who screened positive for depression was started on treatment for depression at
the time of the initial depression screening visit.
During the post-test portion of the study, the fifty-one charts were reviewed after
screening and implementation of treatment measures by the providers in order to compare
the chosen treatment options in both practices. All of the providers documented the
utilization of depression counseling during the initial visits, including the use of
educational handouts regarding depression printed from the electronic medical record.
SSRIs were the most frequently utilized Pharmacotherapy treatment choice in each
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practice, followed by the use of Bupropion. Follow up appointments ranged from 1-2
weeks dependent upon other comorbid conditions and severity of depressive symptoms.
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Chapter 5 Discussion
5.1 Introduction
Throughout the literature review and at completion of the DNP quality
improvement project, recommendations have been identified to assist primary care
providers in improving the quality and timeliness of care delivered to cardiovascular
patients who are suffering from depression. Timely screening, detection, and treatment of
depression in patients with cardiovascular disease may help to improve quality of life and
increase overall survival for these patients (Sin, et al., 2014). The purpose of this chapter
is to discuss recommendations for practice, education, research, and health policy based
on the findings of this project and evidence-based literature.
5.2 Recommendations for Practice
According to the quality improvement project and consistent with the literature,
patients with cardiovascular disease are at high risk for depression and should be
routinely screened to improve quality of life and patient outcomes (McGuire, et al., 2015;
Mavrides & Nemeroff, 2013). Nearly one third of the sample screened positive for
depression (DNP Project, Ballentine, 2017). Through an evaluation of the available
depression screening tools, synthesis of the literature revealed that the PHQ-2 and PHQ-9
tools are the most brief, sensitive, and specific depression screening tool for patients with
cardiovascular disease (Ceccarini, et al., 2014; Mavrides & Nemeroff, 2013). In this
quality improvement project, the PHQ-9 screening tool was found to have a sensitivity of
90% and specificity of 90% (DNP Project, Ballentine, 2017). These results are similar to
58

findings in multiple studies where PHQ-9 scores greater than 10 have been found to have
a sensitivity of 88% and a specificity of 88% for Major Depressive Disorder (APA, 2016;
Stafford, et al., 2007).
Findings from the quality improvement project underscored the need for primary
care providers to utilize the patient health questionnaire (PHQ) screening tool as the
standard for screening in patients with cardiovascular disease due to the incidence of
depression in cardiovascular patients and the tool’s efficacy and ease of use. The PHQ
screening tools are a cost-effective, reliable, valid, and time-efficient approach to
improving patients’ quality of life (McGuire, et al., 2015; Ceccarini, et al., 2014). In
patients with positive depression scores, the provider should review the answers with the
patient, and treatment options should be discussed with the patient.
Also, consistent with the literature, providers in the quality improvement project
chose SSRIs most frequently in the treatment of their patients who screened positive for
depression. There is considerable evidence from randomized controlled clinical trials that
antidepressants, especially SSRIs, are safe in the treatment of major depression in
patients with CVD (Mavrides & Nemeroff, 2013). Researchers have concluded that
frequent and timely treatment initiation by primary care providers, along with increased
patient self-monitoring, leads to improved control of depression and cardiovascular
disease (Mavrides & Nemeroff, 2013; Kronish, et al., 2012; McGuire, et al., 2015).
Evidence also suggests that depressed patients who are not responsive to treatment for
depression may be at greater risk for adverse cardiac events, but aggressive cardiologic
care may help mitigate this increased risk (Lichtman et al., 2008). Depressed patients
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may also require additional clinical management to ensure compliance with cardiac
treatment regimens and to promote lifestyle behavior change.
Providers must be prepared to refer depressed patients when necessary. During
the quality improvement project, one patient from each practice stated that they recently
had thoughts of self-harm, and these patients were promptly referred for further
psychiatric evaluation and treatment. Appropriate follow up appointments should be
scheduled for all patients with depressive symptoms in order to monitor progress and
responses to treatment.
5.3 Recommendations for Education
Prior to implementation of the quality improvement screening tool, providers and
nursing staff were educated on the use of the PHQ tool. Formal and clear procedures,
mechanisms, regular case reviews, and peer staff development need to be in place in
order to sustain a successful screening program and offer an environment which aids in
bringing about the best outcome for the patient dealing with depression. Depression
screening in primary care should be included in continuing medical education
requirements for providers working in the primary care setting (Agren et. al., 2014;
Lichtman et al., 2008; Mavrides & Nemeroff, 2013).
Providers and staff should educate patients and families on the potential impacts
of depression on their health and quality of life. Patients and families should also be
educated on the importance of compliance with treatment regimens in the successful
treatment of depression. During this quality improvement project, providers documented
counseling the patients with depression 100% of the time.
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Psychoeducational counseling and intervention have been found to reduce
anxiety and depression in patients with cardiovascular disease, and educational
interventions increase patient and family satisfaction (Agren et. al., 2014). When the
families and the patients are well-informed, there is a basis for fruitful and effective
communication between them and the healthcare professionals leading to increased
compliance to treatment regimens and overall better outcomes (Agren et al., 2014).
5.4 Recommendations for Research
Adequately powered and randomized clinical trials remain necessary to develop
refinements in screening tools and collaborative care models which can lead to even
greater improvements in mental health and function in patients with CVD (Huffman, et
al., 2014). Researchers suggest that further research efforts to address increased mortality
in depressed patients with cardiovascular illnesses should focus on processes that impact
cardiac functional status (Huffman, et al., 2014). Additional research is needed to
properly characterize evidence-based care of patients with comorbid depression and
cardiovascular disease. Also, more trials are needed before the recognition and treatment
of depression becomes part of the routine clinical care of patients with cardiovascular
disease due to several factors including time constraints in primary care practice and lack
of standardized depression screening across specialties.
Randomized controlled trials are warranted to examine existing and newer
depression treatment strategies in patients with cardiovascular disease. In one clinical
trial, sertraline led to improvement in depressive symptoms without any increased risk of
adverse cardiac events (Shapiro, et al., 1999). However, data on potential harms such as
adverse effects of antidepressants in patients with cardiovascular disease are quite
61

limited. The new RCTs should be designed with extended periods of follow-up that
enable more complete ascertainment of side effects and potential harm of antidepressant
use. More trials such as these are needed to examine the effect of SSRIs and other
available treatments on mortality and cardiac events.
5.5 Recommendations for Health Policy
According to Healthy People 2020, the burden of mental illness in the United
States is among the highest of all diseases, and mental disorders are among the most
common causes of disability (USDHHS, 2014). The Healthy People 2020 goal is to
“improve mental health through prevention and by ensuring access to appropriate, quality
mental health services” (2014). The U.S. Preventive Services Task Force (2010)
recommends screening adults for depression when staff-assisted depression care supports
are in place to assure accurate diagnosis, effective treatment, and follow-up. Persons at
increased risk of depression are considered at risk throughout their lifetime, and groups at
increased risk include persons with chronic medical diseases such as cardiovascular
disease (USPSTF, 2010). Chronically ill Medicare beneficiaries with accompanying
depression have significantly higher health care costs than those with chronic diseases
alone (Unützer, 2009).
Several recent changes in healthcare policy have promoted access to mental
health for the population; however, there continues to be a significant gap in care for
people with mental health disorders in the United States (CDC, 2011). These changes
include detection and treatment of depression in patients with comorbid chronic illnesses
and older adults. The 2005 White House Conference on Aging adopted a resolution to
improve recognition, assessment, and treatment of mental illness and depression among
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older Americans (CDC, 2011; WHCOA, 2005). Medicare Part B covers one depression
screening per year, and these screenings must be administered in a primary care setting
that can provide follow-up treatment (CMS, 2017).
Limited access to care continues to be a problem for people with mental health
disorders in the United States. Barriers to care include mental healthcare provider
shortages. Although healthcare reform has reduced the rates of uninsured adults, many
adults in the United States remain uninsured which presents another barrier to care. It is
important to support all levels of government to adopt mental health policies and to
integrate mental health policy into public health policy and general social policy.
As the Federal Government continues to implement the health reform legislation,
it will bring attention to providing services for individuals with mental health disorders,
including new opportunities for access to and coverage for treatment and prevention
services (USDHHS, 2014). It would be beneficial to ensure mental health is included in
generic health reforms that are occurring, such as development of health information
systems, quality improvement initiatives, basic training and continuing education
standards, and accreditation procedures. Health policy should promote population-level
depression screening programs based on the literature and current screening guidelines.
Mental health reform policies should also seek to improve the current grant program
related to integration of mental health and primary care with a new approach to drive
significant reforms that improve care and health outcomes for patients with mental health
disorders. Primacy care providers should have incentives to screen routinely per current
guidelines such as those of the USPSTF (2010).
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5.6 Limitations
With regard to limitations of the quality improvement project, the sample size was
relatively small (n=51), and this may increase threats to external validity of the project.
The patients were chosen by appointment date, which increased randomization, thereby
minimizing threats to the internal validity of the project. The results of the screening
surveys and implemented interventions were similar between both practices, which
increases the generalizability of the results and recommendations from the project. The
length of time for the project was a significant limitation to this study, allotting the
providers only 2 months to implement the depression screening tool and treatment plan
for the patients.
5.7 Conclusion
Despite the devastating consequences, comorbid cardiovascular disease and
depression remain poorly recognized and treated (Paz-Filho, 2010; Lichtman et al.,
2008). Primary care providers are called upon to improve their recognition of depression
in their patients and assure prompt treatment is initiated in these patients (Lichtman et al.,
2008). There is a vast literature on depression in cardiovascular patients, and
recommendations have been made for providers in primary care practices with the
purpose of standardizing routine screening for depression in cardiovascular patients in
primary care. Based on the evidence and findings of this project, recommendations
include screening for and treatment of depression in these patients, as well as
recommendations for provider, staff, patient, and family education throughout the
screening and treatment processes (Lichtman et al., 2008; Mavrides & Nemeroff, 2013;
Agren et. al., 2014).
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With regard to screening tools, the PHQ-2 and PHQ-9 questionnaires are the most
brief, sensitive, and specific depression screening tool for patients with cardiovascular
disease (Ceccarini, et al., 2014; Mavrides & Nemeroff, 2013). The PHQ-9 is based
directly on DSM-IV diagnostic criteria for major depression, and this tool has shown to
be valid and reliable after having been widely utilized in studies with cardiac patients
(Stafford et al., 2007).
Multiple safe treatment options exist for patients who test positive for depressive
symptoms with SSRIs being shown as especially safe and effective in patients with
cardiovascular disease (Davidson, et al., 2010; Mavrides & Nemeroff, 2013). Also,
recommendations have been made for further research into this area of study in order to
support standardized screening protocols that might facilitate improved processes for
patients with depression with cardiovascular disease in all primary care settings
(Huffman et. al., 2014).
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Appendix A: Evidence Table
Brief Reference, Type
of study, Quality rating
Mavrides, N. &
Nemeroff, C. (2013).

Treatment of depression
in cardiovascular
disease. Depression and
Anxiety, 30: 328-341.
doi: 10.1002/da.22051.
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Systematic Review of
RCTs

Level I Evidence

Quality Rating: A –
High Quality

Methods

Threats to validity/ reliability

Findings

Conclusions

Systematic Review of 61
randomized controlled
clinical trials. PubMed and
PsycINFO databases were
searched through July 2012.
No trials were excluded, and
the studies included were
primarily from North
America and Europe. The
search was completed with
key words of antidepressants,
CVD, coronary artery
syndrome, SSRIs, depression,
treatment of depression, postMI, major depression, and
cardiac disease.

Internal Validity: The studies
contained in this review are
randomized control clinical trials,
and this helps to minimize threats to
internal validity. The authors stated
that they limited search results to the
English language. By limiting to
English only, the researchers risk
biasing the amount of research they
may find with regard to their
research topic.

A total of 61 articles and
book chapters were
included. There is strong
evidence for a bidirectional
association between
depression and CVD.
Short-term treatment of
depression with TCAs is
relatively safe in patients
with ischemic heart disease,
heart failure, or previous
MI. In general, the SSRIs
are safe and probably
effective in treating
depression in patients with
ischemic heart disease.

There is
considerable
evidence from
these randomized
controlled clinical
trials that
antidepressants,
especially SSRIs,
are safe in the
treatment of major
depression in
patients with CVD.
Although efficacy
has been
demonstrated in
some, but not all,
trials for both
antidepressants
and certain
psychotherapies,
large, wellpowered trials are
urgently needed.

External Validity: The number of
studies reviewed is 61, which should
help to limit threats to external
validity. The results were consistent
across all studies increasing the
generalizability of the results to the
general population.

Reliability: The authors displayed
their results of all utilized clinical
trials in an evidence table, and
discussed odds ratios (OR), effect

sizes, and confidence intervals (CI)
for the trials. The researchers
compared the results of each study,
which limits threats to reliability in
this review.
Peters, R., Pinto, E.,
Beckett, N., Swift, C.,
Potter, J., McCormack,
T., … Bulpitt, C. (2010).
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Association of
depression with
subsequent mortality,
cardiovascular morbidity
and incident dementia in
people aged 80 and over
and suffering from
hypertension. Data from
the Hypertension in the
Very Elderly Trial
(HYVET). Age and
Ageing, 39: 439-445.
doi:
10.1093/ageing/afq042.

Randomized Control
Trial

Double-blind RCT of
2,656 participants.
The HYVET was a
randomized doubleblind, placebocontrolled trial and
employed an
antihypertensive
treatment regimen of
indapamide sustained
release 1.5 mg with
the optional addition
of perindopril 2–4
mg. Ethical and
regulatory approvals
were obtained prior
to data collection.
Depression scores
were collected using
the 15-item GDS
administered as part
of a Quality of Life
(QoL) questionnaire
at baseline and
annually thereafter.

Internal Validity: This was a double-blind
RCT; therefore, the subjects were randomly
assigned to experimental and control groups,
and the subjects and providers were kept
blind to the study group. Double-blinding
helps to significantly minimize threats to
internal validity by reducing selection bias
(Dearholt & Dang, 2012).

External Validity: This was a large study of
2,656 participants, and this minimizes threats
to validity. The subjects in each of the
groups were similar with regard to
demographic and baseline clinical variables,
which makes the results more generalizable.
Baseline demographics were clearly
displayed in a table to complement the
discussion in the article. Although
participants were unable to enter the study if
they required nursing care, the researchers
did not collect rigorous information about
activities of daily living, disability levels or
maintenance of social networks,
socioeconomic status or activity level.

The researchers found that
a GDS score of ≥6 was
associated with an
increased risk of all-cause
and cardiovascular
mortality and
cardiovascular morbidity.
Mood was found to be
worse in those who
previously had a cardiac
event. GDS score ≥6 was
associated with increased
risks of all-cause (HR 1.8,
95% CI 1.4–2.3) and
cardiovascular mortality
(HR 2.10, 95% CI 1.5–3.0),
all stroke (HR 1.8, 95% CI
1.2–2.8) and all
cardiovascular events (HR
1.6, 95% CI 1.2–2.1). Risk
of incident dementia also
tended to be increased (HR
1.28, 95% CI 0.95–1.73).

Depressed mood is
common in older
people with
hypertension.
Higher depression
scores were
associated with an
increased risk of a
subsequent
cardiovascular
event, mortality
and possibly
dementia. The
researchers suggest
that further studies
would require
replication and
exclusion of some
alternative
possibilities (such
as following up a
population known
to be free of
vascular disease or
disability at

Level I Evidence

Quality Rating: A –
High Quality
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Huffman, J.C.,
Mastromauro, C. A.,
Beach, S. R., Celano, C.
M., DuBois, C. M.,
Healy, B. C., …
Januzzi, J. L. (2014).

This is a single-blind
randomized clinical
trial, with study
assessors blind to
group assignment,
from September 2010
through July 2013 of
183 patients admitted
to inpatient cardiac
Collaborative care for
units in an urban
depression and anxiety
academic general
disorders in patients
hospital for acute
with recent cardiac
events: The management coronary syndrome,
of sadness and anxiety in arrhythmia, or heart
failure and found to
cardiology (MOSAIC)
randomized clinical trial. have clinical

Therefore, there is the potential for
uncontrolled confounding from unmeasured
factors. This limits generalizability and
presents possible threats to validity.

baseline, or
carefully
controlling for the
confounding effect
of disability)
before testing in an
intervention trial.

Reliability: Hazard ratios (HR) and
confidence intervals (CI) were discussed indepth, along with p-values. The treatment
effect was large (level of significance), and
the treatment is precise (CI). The large
sample also minimizes threats to reliability.
All results were clearly displayed in tabular
form.
Internal Validity: This is a single-blind study
with randomized assignment to the
experimental and control groups. Study
assessors were kept blind to the study group.
Baseline sociodemographic and medical data
were collected from the electronic medical
record by blinded study staff and from
patients prior to randomization.
External Validity: Unfortunately, this study
was not powered by an appropriate sample
size, which increases the threat to external
validity. The internal and external validity of
the findings are strengthened by concurrent
identification and management of multiple
psychiatric conditions, inclusion of patients
with multiple cardiac diagnoses to include a
substantial proportion of patients admitted to

Patients in the intervention
group were found to have
improvements in depressive
symptoms and general
functioning as compared to
the control group at the end
of the 24-week period.
Patients randomized to CC
had significantly greater
estimated mean
improvements in SF-12
MCS at 24 weeks (11.21
points [from 34.21 to
45.42] in the CC group vs
5.53 points [from 36.30 to
41.83] in the control group;

Collaborative care
(CC) models for
mental health
conditions use
nonphysician care
managers (CMs) to
systematically
identify disorders,
perform
longitudinal
assessments, and
coordinate stepped
treatment
recommendations
between mental
health specialists

JAMA Internal
Medicine, 174(6): 927935.

Randomized Control
Trial

Level I Evidence

depression,
generalized anxiety
disorder, or panic
disorder on structured
assessment. In this
study, 92 patients
were randomized to
the intervention
group and 91 to the
control group (usual
care group).

a typical cardiac unit, use of patient
preference in treatment, inclusion of patients
(10%) who declined treatment as part of the
intent-to-treat design, and centralized postdischarge care management by telephone.

A 3-month
observation period to
identify patients with
ACS and persistent

Internal Validity: This was a randomized
study, which minimizes threats to internal
validity. It was a single-blind trial in which
patients were not blinded to their treatment

Quality Rating: B –
Good Quality
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Davidson, K. W.,
Rieckmann, N.,
Clemow, L., Schwartz,
J. E., Shimbo, D.,

Reliability: Results were displayed in tabular
form. Confidence intervals and effect sizes
were discussed by the researchers. The effect
sizes of the intervention on mental quality of
life, depression, and function were moderate
(0.34 to 0.61), and the effect size on
depression (0.45) is at the upper end of the
range seen in typical collaborative care
depression interventions. These results add to
the reliability of the study and minimize
threats.

estimated mean difference,
5.68 points [95% CI, 2.149.22]; P = .002; effect size,
0.61). Patients receiving
CC also had significant
improvements in depressive
symptoms and general
functioning, and higher
rates of treatment of a
mental health disorder;
anxiety scores, rates of
disorder response, and
adherence did not differ
between groups.

and primary
medical providers.
Collaborative care
and related care
management
interventions for
depression have
improved
treatment and
outcomes in a
variety of
populations,
including patients
with CVD.
Adequately
powered and
randomized trials
remain necessary
to determine
whether
refinements to this
model can lead to
even greater
improvements in
mental health and
function.

At the end of the trial, the
proportion of patients who
were satisfied with their
depression care was higher

Enhanced
depression care for
patients with ACS
was associated

Medina, V., … Burg, M.
M., (2010).
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Enhanced depression
care for patients with
acute coronary
syndrome and persistent
depressive symptoms:
coronary psychosocial
evaluation studies
randomized controlled
trial. Archives of
Internal Medicine,
170(7):600–608.
doi:10.1001/archinternm
ed.2010.29.

Randomized Controlled
Trial

depressive symptoms
was followed by a 6month single-blind
randomized
controlled trial. From
January 1, 2005,
through
February 29, 2008,
237 patients with
ACS from 5 hospitals
were enrolled,
including 157
persistently depressed
patients randomized
to intervention (initial
patient preference for
problem-solving
therapy and/or
pharmacotherapy,
then a stepped-care
approach; 80
patients) or usual care

Level I Evidence

Quality Rating: B –
Good Quality

(77 patients) and 80
non-depressed
patients who
underwent
observational
evaluation.

status for ethical reasons; however, outcome
assessors were blinded.

External Validity: The patients selected for
this trial did not include all patients with
ACS. Researchers excluded those with
cognitive impairments, other life-threatening
conditions, and, most importantly, other
psychiatric conditions such as alcohol or
other drug dependence and bipolar disorder.
Because these comorbid conditions are
highly prevalent in depressed patients, the
findings may not be applicable to all patients
with ACS and depressive symptoms. This
limits generalizability.

Reliability: The researchers discussed odds
ratios (OR), confidence intervals (CI), and
levels of significance for their findings. They
discussed the treatment effect and
preciseness of the intervention. This
minimizes threats to reliability.

in the intervention group
(54% of 80) than in the
usual care group (19% of
77) (OR, 5.4; 95%
confidence interval [CI],
2.2–12.9 [P<.001]). The
Beck Depression Inventory
score decreased
significantly more
(t155=2.85 [P=.005]) for
intervention patients
(change, −5.7; 95% CI,
−7.6 to −3.8; df=155) than
for usual care patients
(change, −1.9; 95% CI,
−3.8 to −0.1; df=155); the
depression effect size was
0.59 of the standard
deviation. At the end of the
trial, 3 intervention patients
and 10 usual care patients
had experienced major
adverse cardiac events
([P=.047]), as well as 5
non-depressed patients
(6%) (for the intervention
vs non-depressed cohort,
[P=.49]).

with greater
satisfaction, a
greater reduction
in depressive
symptoms, and a
promising
improvement in
prognosis. The
researchers suggest
that further trials
of enhanced
depression care are
required to
determine whether
this type of
treatment can
improve post-ACS
prognosis.

Wang, W., Lopez, V.,
Chow, A., Chan, S.,
Cheng, K. K. &
He, H. (2014).
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A randomized controlled
trial of the effectiveness
of a self-help
psychoeducation
programme on outcomes
of outpatients with
coronary heart disease:
study protocol. Journal
of Advanced Nursing,
70(12): 2932–2941. doi:
10.1111/jan.12397.

Randomized Controlled
Trial with Repeated
Measures

Level I Evidence

Quality Rating: B –
Good Quality

In this proposed
randomized
controlled trial, a
convenience sample
of 128 coronary heart
disease outpatients
will be recruited from
a tertiary hospital in
Singapore.
Participants are
randomly assigned to
the 4-week
experimental group
and will participate in
the program or the
control group who
will not participate in
the program. The
outcome measures
include the: 12-item
Short Form Health
Survey, Perceived
Stress Scale, Hospital
Anxiety and
Depression Scale and
General Self-Efficacy
Scale. Data will be
collected at baseline,
then 4 and 16 weeks
from baseline. At the
end, a process

Internal Validity: As the researchers discuss,
the best way to minimize confounding bias is
through the use of randomization. The RCT
proposed for this study will overcome this
limitation and minimize threats to internal
validity.

External Validity: There are many factors
that could influence the results of this study
and its generalizability, such as duration of
illness, age and educational level.

Reliability: In the statistical point of view,
confounding variables can be dealt with
using multivariate repeated measure
ANCOVA. The authors discuss that
confounding variables will be controlled as
covariates in the model for analysis. These
measures will help to minimize threats to
reliability as well as validity of the study.

This RCT was proposed
and received grant funding
in July 2013. According to
the researchers, nature of
this program will benefit
both healthcare providers
and patients. For patients,
this program affords them
the flexibility to carry out
their recovery at their own
time. The program also
may help patients save
money (e.g. transportation,
program charges) and time
when compared with
attending hospital-based
rehabilitation programs. For
the healthcare providers,
the independent nature of
this program will greatly
reduce the amount of
contact time with patients,
which allows them to spend
more time with patients
who require their attention,
for example patients with
acute myocardial infarction.
This will result in a more
efficient use of health
resources in the long run.
Eventually, this program

The proposed
study is in line
with the global
trend in promoting
self-management
for chronic health
conditions. To the
best of research
team’s knowledge,
this is the first
RCT in the region
that incorporates a
home-based selfhelp
psychoeducation
approach for CHD
patients and
evaluates
its effectiveness on
patients’ outcomes,
including HRQoL,
psychological
status, cardiac risk
factors and health
service use. The
proposed RCT will
make a significant
contribution to the
current knowledge
of the effectiveness

evaluation will be
conducted to assess
the acceptability,
strengths and
weaknesses of our
program based on the
participants’
perspectives.

of home-based
self-help programs.
The process
evaluation
included in this
study will help the
research team
understand the
strengths and
weaknesses of this
program. If this
home-based selfhelp
psychoeducation
program is
effective, it can be
an option for CHD
patients in addition
to existing cardiac
rehabilitative
services.

Partners in the intervention
group increased health in
the role emotional and
mental health dimensions,
and patients increased
health in vitality, social
function, and mental health
dimensions as compared
with the control group.

The results of this
study suggest that
psychoeducational
support from a
multidisciplinary
team to post
cardiac surgery
heart failure dyads
improves health
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aims to be available for all
CHD patients living in the
community.

Agren, S., Berg, S.,
Svedjeholm, R., &
Stromberg, A. (2014).

Psychoeducational
support to post cardiac
surgery heart failure
patients and their

Pilot study with a
randomized
controlled design
which included a
total of 42 patientpartner completed
baseline assessments
for evaluating
psychosocial support

Internal Validity: The 42 patient-partner
dyads that chose to participate were
randomized to either the experimental or
control groups. Randomization minimizes
threats to internal validity.

External Validity: There was relatively a
small sample of couples in this study, and

partners—A randomized
pilot study. Intensive
and Critical Care
Nursing, 31: 10-18.
doi:10.1016/j.iccn.2014.
04.005.

Pilot study with a
randomized controlled
design.

Level I Evidence

80
Quality Rating: B –
Good Quality

Grace, S. L., Grewal, K.,
Arthur, H. M.,
Abramson, B. L., &
Stewart, D. E. (2008).

and education from
an interdisciplinary
team approach.
Patients with
postoperative health
failure and their
partners were chosen
to participate in 3
month and 12 month
follow up phone
interviews.
Randomization was
performed using a
random-number table
with block of 12.
Several
questionnaires were
used, including a
demographic
questionnaire,
Charlson
Comorbidity Index,
SF-36, Beck
Depression
Inventory, and
Perceived Control.

this is a threat to external validity. There
were some inter-group differences and
outcomes, which would limit
generalizability.

A prospective,
controlled quasiexperimental 157
female cardiac

Internal Validity: Given the nonrandom
study design, causal conclusions about the
changes realized for female heart patients

Patients’ perceived control
improved significantly in
the intervention group over
time.

and perceived
control in patients
after 3 and 12
months. These
results also suggest
that interventions
focusing on
psychoeducational
support can
improve the life
situation for the
patient-partner and
especially for the
patients.
Psychoeducational
support appears to
be a promising
intervention but
the results need to
be confirmed in
larger studies.

Researchers found that 51
(45.1%) of the women selfreported participating in CR
at 1 of 18 sites, and site-

Following a
cardiac event,
female patients
improved their

Reliability: The researchers discussed the
levels of significance for their results and
placed these results in a table. The small
sample size may have influenced that the
difference between the groups did not reach
statistical significance. This is a threat to
reliability. As the researchers discuss, this
was only a pilot study, and larger studies
need to be undertaken.

A Prospective,
Controlled Multisite
Study of Psychosocial
and Behavioral Change
Following Women’s
Cardiac Rehabilitation
Participation. Journal of
Women’s Health, 17(2):
241-248. doi:
10.1089/jwh.2007.0519.
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Prospective, Controlled
Quasi-Experimental
Design

Level II Evidence

Quality Rating: A –
High Quality

inpatients from three
hospitals consented to
participate in a
prospective study,
and 110 (79%) were
retained 18 months
post-discharge. A
mailed survey
discerned CR
participation 9
months postdischarge. Quality of
life (Short-Form
Health Survey
Physical and Mental
Component Summary
[SF-12 PCS and
MCS]), exercise
behavior (HealthPromoting Lifestyle
Profile II [HPLPII]),
Exercise Benefits and
Barriers Scale
(EBBS), and anxiety
and depressive
symptoms (Hospital
Anxiety and
Depression Scale
[HADS]) were
assessed in hospital

cannot be drawn. Non-randomization
increases the threat to internal validity.

External Validity: Generalizability is limited
by the selection biases and differences
between CR participants and nonparticipants.
In particular, and as shown in other studies,
49, 51, 52 CR participants were more likely
to have had ACS or an ACB than a PCI and
were better educated than nonparticipants.
Also, because of the small number of women
in the sample, lack of power may be masking
changes.

Reliability: The use of self-report measures
is open to social desirability bias and other
errors in reporting. Specifically, self-report
of exercise behavior may be biased. The
method through which the results were
obtained poses a threat to reliability.

verified participation was
82.43% _ 29.97% of
prescribed sessions. For CR
participants, paired
t tests assessing change
from hospitalization to 18
months post-discharge
revealed significant
improvements in physical
quality of life (p _ 0.001),
anxiety (p _ 0.05), and
exercise behavior (p _
0.01). Women who did not
participate in CR
experienced significant
improvements in physical
quality of life (p _ 0.02),
and depressive symptoms
(p _ 0.03) but not exercise
behavior.

physical quality of
life and affect, but
only patients who
participated in CR
increased their
exercise behavior.
Given the cardiac
benefits of exercise
and that women
are often sedentary
and given that this
exercise behavior
was sustained postCR, these findings
are significant. A
sufficiently
powered
randomized
controlled
trial of women’s
outcomes after CR
participation is
greatly
needed.

and 18 months postdischarge.
McGuire, A. W.,
Ahearn, E. & Doering,
L. V. (2015).

Psychological distress
and cardiovascular
disease. Journal of
Clinical Outcomes
Management, 22(9),
421-432.
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Systematic Review

Level II Evidence

Systematic Review of
relevant and current
(2005–2015) clinical
trials was performed
by a series of
searches conducted in
the PubMed and
PsychINFO databases
using Boolean
terms/phrases along
with manual
extraction from the
reference lists of
pertinent studies. The
researchers narrowed
their results and
utilized 18 relevant
articles for this study.

Internal Validity: All studies included were
experimental clinical trials; however, not all
studies utilized randomization. Nonrandomization increases the threat to internal
validity through bias.

Participants were
recruited between
May 2005 and March

Validity: The internal consistencies of the
results were excellent. In terms of the
generalizability of these findings, this study

Quality Rating: B –
Good Quality

Stafford, L., Hons, M.
A., Berk, M., & Jackson,
H. J. (2007).

External Validity: The researchers presented
results from 18 studies, which is a small
number of studies and potentially presents a
threat to external validity. The results were
consistent across all studies increasing the
generalizability of the results to the general
population.

Screening for psychological
distress in CVD is
recommended. Referral and
treatment issues need
further exploration.
Pharmacologic treatment of
psychological distress in
CVD remains equivocal;
however, promising data
exists for other therapies
such as cognitive
behavioral therapy and
social support strategies.

Psychological
distress has a
significant
negative impact on
patients with CVD
and is underrecognized by
health care
providers. Primary
care providers and
cardiovascular
specialty providers
are called upon to
improve their
recognition of
psychological
distress in their
patients and assure
referrals are made
to collaborative
care teams for
proper diagnosis
and treatment.

One hundred and ninetythree of the recruited
patients

Criterion validity
for the PHQ-9 and
HADS was good,

Reliability: The authors displayed their
results of all utilized clinical trials in an
evidence table, and discussed odds ratios
(OR), confidence intervals (CI), and p-values
for the trials. The significance (ORs, effect
sizes, level of significance) of the treatment
effects and the preciseness (CI) of the studies
utilized limit threats to reliability.
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2006 from the
Geelong Hospital in
Validity of the hospital
Victoria, Australia.
anxiety and depression
All were Englishscale and patient health
speaking patients
questionnaire-9 to screen
who resided
for depression in
permanently in
patients with coronary
Australia and were
artery disease. General
hospitalized for
Hospital Psychiatry,
percutaneous
29(5): 417-424.
transluminal coronary
doi:10.1016/j.genhospps
angioplasty (PTCA),
ych.2007.06.005
AMI or coronary
artery bypass graft
surgery (CABG)
Quasi-experimental
during this time were
study with post-test only eligible for
design
participation. There
were no other
exclusion criteria.
Level II Evidence
Two hundred and
twenty-nine patients
agreed to participate
in the study. The
Quality Rating: A –
HADS and PHQ-9
High Quality
measures were
mailed to
participants 3 months
post-discharge.

included patients recently hospitalized for
cardiac disease. It is unknown whether the
results from this analysis would generalize to
PHQ-9 and HADS scores among other
populations or to patients with other
comorbidities.

Reliability: A possible limitation of this
study is that participants were required to
complete two measures of depression in one
questionnaire pack. Although other measures
were placed between these two instruments,
and the structure and content of these two
instruments differ, effects of repetition or
order cannot be excluded. The use of selfreport measures is open to social desirability
bias and other errors in reporting.
Specifically, self-report of exercise behavior
may be biased. The method through which
the results were obtained poses a threat to
reliability.

(84.3%) completed both the
structured clinical interview
and the self-report
questionnaires. Twentyeight participants did not
return their questionnaires
for an unknown reason, 3
withdrew due to physical
illness and 4 withdrew due
to depression. Thirty-five
participants met diagnostic
criteria for major
depression (male=24;
female=11), 13 for minor
depression (male=10;
female=3) and 6 for
dysthymia (male=6;
female=0), corresponding
to a 3-month post-discharge
depression rate of 28%.
Nine (4.7%) of the 193
participants
met criteria for both major
depressive disorder and
dysthymia, so-called
“double depression”. The
internal consistencies for
the self-report
questionnaires were
excellent with Cronbach's α

and both
instruments can be
recommended to
identify any
depressive disorder
and major
depressive disorder
in recently
hospitalized
patients with CAD.
Diagnostic
superiority of the
PHQ-9 over the
HADS for major
depressive disorder
was reported. Both
instruments have
acceptable
properties for
detecting
depression in
recently
hospitalized
cardiac patients.

coefficients of 0.90 and
0.81 for the PHQ-9 and
HADS, respectively. The
intercorrelation between the
HADS and PHQ-9 was
0.72.
Paz-Filho, G., Licinio,
J., & Wong, M. (2010).
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Pathophysiological basis
of cardiovascular disease
and depression: a
chicken-and-egg
dilemma. Revista
Brasileira de
Psiquiatria, 32(2): 181191. Retrieved from:
http://www.ncbi.nlm.nih
.gov/pmc/articles/PMC4
259495/pdf/nihms64533
2.pdf
Systematic Review

Level III Evidence

Quality Rating: B –
Good Quality

A systematic
literature review of a
combination of
RCTs, quasiexperimental studies,
and non-experimental
studies. The
reviewers utilized the
PubMed database in
order to describe the
pathophysiological
link between
cardiovascular
disease and
depression.
The manuscripts
included in the article
were selected based
on their
methodological
aspects and the
strength of their
findings.

Validity: Several non-experimental studies
were included in the review. This increases
the threat to internal validity. The results
were consistent across all studies increasing
the generalizability of the results to the
general population.

Reliability: The researchers did not include a
specific analysis of the levels of evidence of
the studies which they included in their
review. This is an increased threat to
reliability of the review.

Depression and
cardiovascular disease are
both highly prevalent.
Several studies have shown
that the two are closely
related. They share
common
pathophysiological
etiologies or comorbidities, such as
alterations in the
hypothalamic-pituitary axis,
cardiac rhythm
disturbances, and
hemorheologic,
inflammatory and
serotoninergic changes.
Furthermore, antidepressant
treatment is associated with
worse cardiac outcomes (in
case of tricyclics), which
are not observed with
selective serotonin reuptake
inhibitors.

There is irrefutable
evidence that
depression and
CVD share
common pathways.
Both of these
conditions are
stress-reactive
disorders of
unknown etiology.
To minimize
morbidity and
mortality, it is
crucial to
understand that
MDD and CVD
are frequently comorbid and that
both conditions
should be treated
concomitantly, as
the treatment of
depression
improves the
patient’s quality of
life and their

Sin, N. L., Yaffe, K., &
Whooley, M. A. (2014).
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Depressive symptoms,
cardiovascular disease
severity, and functional
status in older adults
with coronary heart
disease: The Heart and
Soul Study. Journal of
the American Geriatrics
Society, 63: 8-15.
doi:10.1111/jgs.13188.

Prospective Cohort
Study

Level III Evidence

Quality Rating: A –
High Quality

A prospective cohort
study designed to
examine how
psychosocial factors
influence clinical
outcomes in
individuals with
coronary heart
disease. The sample
comprised 960
participants. The
severity of depressive
symptoms was
assessed at baseline
and at the 5-year
follow-up using the
9-itme Patient Health
Questionnaire (PHQ).
Cardiovascular
severity assessments
were obtained at
baseline and again at
5 years.

Internal Validity: There was a well-defined
and representative sample of patients at
similar points of cardiovascular severity.
Follow-up was sufficiently long and
complete at the end of the 5-year period.
These factors minimize threats to internal
validity.

External Validity: It is unknown whether the
findings may be generalized to older
populations, such as those aged 75 and older,
since the average of patients was 67. The
sample was also largely male, and many
were veterans, although other characteristics
of the sample were representative of
individuals with CHD, including ethnic
diversity (40% were nonwhite) and a wide
range of diagnoses. These factors pose
threats to external validity. Also, a number of
confounding variables may have been
responsible for the association between
depressive symptoms and functional decline,
although demographic characteristics, BMI,
comorbid conditions, and health behaviors
were adjusted for, suggesting that these
variables did not explain the relationship

Over 5 years, the
researchers found higher
baseline depressive
symptoms predicted greater
risk of functional decline,
whereas higher baseline
exercise capacity was
associated with lower risk
of functional decline. In
658 of the participants, 5year changes in depressive
symptoms and exercise
capacity were associated
with 5-year changes in
functional status as well.

adherence to a
regimen of
medication for
CVD.
In older adults
with coronary
heart disease,
depressive
symptoms and
lower exercise
capacity predicted
functional decline
over 5 years. In
contrast, other
traditional
measures of
cardiovascular
severity such as
angina pectoris
were not
independently
predictive of
subsequent
functional status.
These results
suggest that efforts
to treat and
decrease
depressive
symptoms may be
as important as

between depressive symptoms and functional
status. The researchers attempted to adjust
for important confounding variables, but list
this as a threat to external validity and a
limitation of the study.

treating actual
symptoms of
cardiovascular
disease to enhance
functional status.
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Reliability: The researchers discuss the
magnitude of the relationship between
predictors (RR) and the preciseness of the
study estimates (CI), which minimize threats
to reliability. As the researchers discuss, it is
unknown whether the results would differ if
more-frequently assessed, short-term
relationships, such as associations between
changes in angina pectoris and functional
status every 6 months, were examined. This
poses a threat to the reliability of the results.
Eurelings, L. S. M.,
Ligthart, S. A., van
Dalen, J. W., van
Charante, E. P., van
Gool, w. A., & Richard,
E. (2013).

Apathy is an
independent risk factor
for incident
cardiovascular disease in

A prospective cohort
study of 1810
community-dwelling
older individuals
(70–78 years of age)
without a history of
CVD or stroke.
Symptoms of apathy
and depression were
assessed with the 15item Geriatric
Depression Scale.

Internal Validity: There was a well-defined
and representative sample of patients at
similar points of cardiovascular severity.
Follow-up was sufficiently long and
complete at the 2-year follow-up. These
factors minimize threats to internal validity.

External Validity: The large sample size of
1,810 older individuals minimizes threats to
external validity, and the results are easily
generalizable to patients within the included

Symptoms of apathy and
depression were present in
281 (15.5%) and 266
(14.7%) participants,
respectively. Incident CVD
occurred in 62 (3.5%)
participants and stroke in
55 (3.1%) participants.
Apathy was associated with
incident CVD after
adjustment for
demographics and

Symptoms of
apathy in older
persons without a
history of
cardiovascular
disease or stroke
are highly
prevalent and are
strongly associated
with incident
cardiovascular
disease. This

the older individual: a
population-based cohort
study. International
Journal of Geriatric
Psychiatry, 29: 454-463.

Prospective Cohort
Study

Level III Evidence
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Incident CVD and
stroke were assessed
after 2 years followup. The associations
of symptoms of
apathy and
depression with
incident CVD and
stroke were analyzed
separately using
logistic regression
analysis.

age group. The researchers also adjusted for
confounding variables, which limits threats
to external validity.

Meta-analyses and
meta-regression

Internal Validity: The methodological
quality of every study utilized for this review

Reliability: The researchers discussed odds
ratios (OR), confidence intervals (CI), and
levels of significance for their findings. They
discussed the treatment effect and
preciseness of the intervention. This
minimizes threats to reliability.

cardiovascular risk factors
(odds ratio (OR) = 2.60,
95% CI = 1.46–4.65).
Exclusion of subjects with
depressive symptoms
yielded a similar OR (2.94,
95% CI = 1.45–5.96, n =
1544).

association is
independent from
well-established
cardiovascular risk
factors and from
the presence of
depressive
symptoms.
Therefore, apathy
can be considered
as an important
risk factor for
incipient
cardiovascular
disease. Since the
nature of these
symptoms may
lead to a tendency
to withdraw from
clinical care, this
emphasizes the
need for
recognition of
apathy symptoms
in older persons
without previous
cardiovascular
disease or stroke.

After inclusion and
exclusion criteria, 28

The results of this
elaborate

Quality Rating: A –
High Quality

Van der Kooy, K., van
Hout, H., Marwijk, H.,

Marten, H., Stehouwer,
C., & Beekman, A.
(2007).

Depression and the risk
for cardiovascular
diseases: systematic
review and meta
analysis. International
Journal of Geriatric
Psychiatry, 22: 613-626.
doi: 10.1002/gps.1723
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Systematic Review and
Meta-Analysis of NonExperimental Studies

Level III Evidence

Quality Rating: A –
High Quality

analyses of
longitudinal cohort
and case-control
studies reporting
depression at baseline
and CVD outcomes
at follow-up. The
following databases
were utilized in this
project: Medline
(1966–2005) and
PSYCHINFO (1966–
2005). The following
search terms were
used: depression,
depressive disorder,
depressi* (truncated),
cardiovascular
diseases, myocardial
ischemia, coronary,
infarct* (truncated),
ischemic, heart
diseases.

was independently assessed by two of four
reviewers, who were blinded for author and
journal. Researchers used a standardized
checklist of predefined quality criteria for
prognostic cohort and case-control studies,
based on the checklist. The checklist
comprised 18 items concerning internal
validity, generalizability, and precision,
which could be scored as positive, negative
and
unclear. These methods should minimize
threats to validity and reliability. The
researchers only included published studies
and left out unpublished studies. This
presents an issue of publication bias which is
a threat to validity.

External Validity: There were 28 studies
contained in this study. Of these the
researchers felt that 11 studies were high
quality evidence.

Reliability: The authors displayed their
results of all utilized studies in an evidence
table, and discussed odds ratios (OR),
confidence intervals (CI), and p-values for
the trials. The significance (ORs, effect sizes,
level of significance) of the treatment effects

articles were chosen. The
risk of depression for CVD
onset was higher in
populations that were free
of CVD at baseline.

systematic metaanalysis and metaregression analysis
confirm that
depression is
associated with the
development of
various CVDs in
communitydwelling and
general practice
populations.
Depressed mood
moderately
increased the risk
for MI, CHD,
cerebrovascular
diseases and other
CVDs to the same
level (1.43–1.63).
Only the combined
risk of the MIstudies, the group
with the strictest
IC-10 definition,
did not suffer from
heterogeneity.
There was a great
methodological
variation among

and the preciseness (CI) of the studies
utilized limit threats to reliability.
Hare, D. L., Toukhsati,
S. R., Johansson, P. &
Jaarsma, T. (2014).
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Depression and
cardiovascular disease:
A clinical review.
European Heart
Journal, 35: 1365-1372.
Retrieved from:
http://eurheartj.oxfordjo
urnals.org/content/ehj/35
/21/1365.full.pdf

Systematic Clinical
Review of experimental
studies

Level III Evidence

Quality Rating: B –
Good Quality

Clinical review of
five major
randomized
controlled trials to
evaluate the effects of
anti-depressant
pharmacotherapy on
depression in
cardiovascular
disease settings.

Validity: A total of five randomized control
trials were reviewed. The researchers felt that
these were all high quality evidence. The five
trials included significant numbers of
patients ranging from 101 to 2,481.
However, the low number of studies
included limits the validity of the review.

Reliability: The authors clearly displayed the
results of all utilized studies in an evidence
table, and this limits threats to reliability.

the selected
studies.
Cardiovascular disease is
the leading cause of death,
disability, and disease
burden in the developed
world. Depression is
common in CVD patients
and is linked to higher
mortality and morbidity
rates. An American Heart
Association Science
Advisory suggested that the
PHQ screening tools appear
to be the most useful in this
population of patients.

There is sufficient
evidence to
support the
introduction of
exercise, talking
therapies, and antidepressant
medications to
reduce depression
in CVD patients.
Although research
has yet to clearly
and consistently
identify
cardiovascular
benefits in this
regard, depression
is a fundamental
determinant of
quality of life in
these patients.
Many questions
remain, and further
research is clearly
required to unravel
potential
pathophysiological
mechanisms and

to determine both
the best
management
strategies and the
effects on clinical
outcomes.
Lichtman, J. H., Bigger,
J. T., Blumenthal, J. A.,
Frasure-Smith, N.,
Kaufmann, P. G.,
Lespérance, F.,
…Froelicher, E. S.
(2008).
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Depression and coronary
heart disease
recommendations for
screening, referral, and
treatment: A science
advisory from the
American Heart
Association Prevention
Committee of the
Council on
Cardiovascular Nursing,
Council on Clinical
Cardiology, Council on

This is a
multispecialty
consensus document
which provides
experts’ opinions and
reviews of the
evidence linking
depression with CHD
and provides
recommendations for
healthcare providers
for the assessment,
referral, and
treatment of
depression. A group
of experts reviewed
60 prospective
studies and 100
narrative reviews on
which they based
their conclusions and
recommendations for
healthcare providers.

Internal Validity: The researchers discuss
several non-experimental studies, and this
increases threats to internal validity.

External Validity: Despite differences in
sample sizes, duration of follow-up, and
assessment of depression and depressive
symptoms, these studies included in the
experts’ review have demonstrated relatively
consistent results. This minimizes threats to
validity and increases generalizability.

Reliability: The researchers reviewed a large
number of articles, and this adds to the
reliability of their conclusions and
recommendations.

The following
recommendations were
made by the American
Heart Association:
At a minimum, the Patient
Health Questionnaire
(PHQ-2) provides 2
questions that are
recommended for
identifying currently
depressed patients. If the
answer is “yes” to either or
both questions, it is
recommended that all 9
PHQ items (PHQ-9) be
asked. For patients with
mild symptoms, follow-up
during a subsequent visit is
advised. In patients with
high depression scores, a
physician or nurse should
review the answers with the
patient. There is no
evidence that treatments for

The high
prevalence of
depression in
patients with CHD
supports a strategy
of increased
awareness and
screening for
depression in
patients with CHD.
Specifically,
routine screening
for depression in
patients with CHD
in a variety of
healthcare settings
and coordination
of care among
healthcare
providers.

Epidemiology and
Prevention, and
Interdisciplinary Council
on Quality of Care and
Outcomes Research.
Circulation, 118: 17681775. doi:
10.1161/circulationAHA
.108.190769

Clinical Practice
Guidelines

91

Level IV Evidence

depression are differentially
effective in cardiac versus
other patients.
Evidence also suggests that
depressed patients who are
not responsive to treatment
for depression may be at
greater risk for adverse
cardiac events. Aggressive
cardiologic care may help
mitigate this increased risk.
Depressed patients may
also require additional
clinical management to
ensure compliance with
cardiac treatment regimens
and to promote lifestyle
behavior change.

Quality Rating: A –
High Quality

Note: Evidence ratings (Level I-IV) and Quality ratings for the literature are based on Dearholt & Dang’s (2012) book John Hopkins
Nursing Evidence-Based Practice: Model and Guidelines.

Appendix B: Evidence Level and Quality Guide
Evidence Levels

Quality Guides

Level I – Experimental studies, Randomized
Control Trials (RCT), Systematic Reviews of
RCTs with or without meta-analysis
Level II – Quasi-experimental studies, Systematic
Reviews of a combination of RCTs and quasiexperimental studies, or quasi- experimental
studies only, with or without meta-analysis
Level III – Non-experimental studies, Systematic
Reviews of a combination of RCTs, quasiexperimental studies, and non-experimental
studies, or non-experimental studies only, with or
without meta-analysis
Qualitative studies or Systematic Reviews with or
without meta-synthesis

A High Quality: Consistent, generalizable results;
sufficient sample for the study design; adequate
control; definitive conclusions; consistent
recommendations based on comprehensive
literature review that includes thorough reference
to scientific evidence.
B Good Quality: Reasonably consistent results;
sufficient sample for the study design; some
control, fairly definitive conclusions; reasonably
consistent recommendations based on fairly
comprehensive literature review that includes
some reference to scientific evidence.
C Low Quality or Major Flaws: Little evidence
with inconsistent results; insufficient sample size
for study design; conclusions cannot be drawn.

Level IV – Opinions of expected authorities and/or
nationally recognized expert committees/consensus
panels based on scientific evidence
Includes: Clinical Practice Guidelines and
Consensus Panels

A High Quality: Material officially sponsored by
professional, public, private, organization, or
government agency; documentation of a
systematic literature search strategy; consistent
results with sufficient numbers of well-designed
studies; criteria-based evaluation of overall
scientific strength and quality of included studies
and definitive conclusions; national expertise is
clearly evident; developed or revised within the
last 5 years.
B Good Quality: Material officially sponsored by
professional, public, private, organization, or
government agency; reasonably thorough and
appropriate systematic literature search strategy;
reasonably consistent results; sufficient numbers
of well-designed studies; evaluation of strengths
and limitations of included studies with fairly
definitive conclusions; national expertise is clearly
evident; developed or revised within the last 5
years.
C Low Quality or Major Flaws: Material not
sponsored by official organization or agency;
undefined, poorly defined, or limited literature
search strategy; no evaluation of strengths or
limitations of included studies, insufficient
evidence with inconsistent results, conclusions
cannot be drawn; not revised within the last 5
years.

(Adapted from Deaholt & Dang, 2012).
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Appendix C: Patient Health Questionnaire Depression Screening Tool
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Appendix D

Stetler’s Model of Evidence-Based Practice
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